BindingDB Reactant_set_id Ligand SMILES Ligand InChI Ligand InChI Key BindingDB MonomerID BindingDB Ligand Name Target Name Target Source Organism According to Curator or DataSource Ki (nM) IC50 (nM) Kd (nM) EC50 (nM) kon (M-1-s-1) koff (s-1) pH Temp (C) Curation/DataSource Article DOI BindingDB Entry DOI PMID PubChem AID Patent Number Authors Date of publication Date in BindingDB Institution Link to Ligand in BindingDB Link to Target in BindingDB Link to Ligand-Target Pair in BindingDB Ligand HET ID in PDB PDB ID(s) for Ligand-Target Complex PubChem CID PubChem SID ChEBI ID of Ligand ChEMBL ID of Ligand DrugBank ID of Ligand IUPHAR_GRAC ID of Ligand KEGG ID of Ligand ZINC ID of Ligand Number of Protein Chains in Target (>1 implies a multichain complex) BindingDB Target Chain Sequence 1 PDB ID(s) of Target Chain 1 UniProt (SwissProt) Recommended Name of Target Chain 1 UniProt (SwissProt) Entry Name of Target Chain 1 UniProt (SwissProt) Primary ID of Target Chain 1 UniProt (SwissProt) Secondary ID(s) of Target Chain 1 UniProt (SwissProt) Alternative ID(s) of Target Chain 1 UniProt (TrEMBL) Submitted Name of Target Chain 1 UniProt (TrEMBL) Entry Name of Target Chain 1 UniProt (TrEMBL) Primary ID of Target Chain 1 UniProt (TrEMBL) Secondary ID(s) of Target Chain 1 UniProt (TrEMBL) Alternative ID(s) of Target Chain 1 BindingDB Target Chain Sequence 2 PDB ID(s) of Target Chain 2 UniProt (SwissProt) Recommended Name of Target Chain 2 UniProt (SwissProt) Entry Name of Target Chain 2 UniProt (SwissProt) Primary ID of Target Chain 2 UniProt (SwissProt) Secondary ID(s) of Target Chain 2 UniProt (SwissProt) Alternative ID(s) of Target Chain 2 UniProt (TrEMBL) Submitted Name of Target Chain 2 UniProt (TrEMBL) Entry Name of Target Chain 2 UniProt (TrEMBL) Primary ID of Target Chain 2 UniProt (TrEMBL) Secondary ID(s) of Target Chain 2 UniProt (TrEMBL) Alternative ID(s) of Target Chain 2 BindingDB Target Chain Sequence 3 PDB ID(s) of Target Chain 3 UniProt (SwissProt) Recommended Name of Target Chain 3 UniProt (SwissProt) Entry Name of Target Chain 3 UniProt (SwissProt) Primary ID of Target Chain 3 UniProt (SwissProt) Secondary ID(s) of Target Chain 3 UniProt (SwissProt) Alternative ID(s) of Target Chain 3 UniProt (TrEMBL) Submitted Name of Target Chain 3 UniProt (TrEMBL) Entry Name of Target Chain 3 UniProt (TrEMBL) Primary ID of Target Chain 3 UniProt (TrEMBL) Secondary ID(s) of Target Chain 3 UniProt (TrEMBL) Alternative ID(s) of Target Chain 3 BindingDB Target Chain Sequence 4 PDB ID(s) of Target Chain 4 UniProt (SwissProt) Recommended Name of Target Chain 4 UniProt (SwissProt) Entry Name of Target Chain 4 UniProt (SwissProt) Primary ID of Target Chain 4 UniProt (SwissProt) Secondary ID(s) of Target Chain 4 UniProt (SwissProt) Alternative ID(s) of Target Chain 4 UniProt (TrEMBL) Submitted Name of Target Chain 4 UniProt (TrEMBL) Entry Name of Target Chain 4 UniProt (TrEMBL) Primary ID of Target Chain 4 UniProt (TrEMBL) Secondary ID(s) of Target Chain 4 UniProt (TrEMBL) Alternative ID(s) of Target Chain 4 BindingDB Target Chain Sequence 5 PDB ID(s) of Target Chain 5 UniProt (SwissProt) Recommended Name of Target Chain 5 UniProt (SwissProt) Entry Name of Target Chain 5 UniProt (SwissProt) Primary ID of Target Chain 5 UniProt (SwissProt) Secondary ID(s) of Target Chain 5 UniProt (SwissProt) Alternative ID(s) of Target Chain 5 UniProt (TrEMBL) Submitted Name of Target Chain 5 UniProt (TrEMBL) Entry Name of Target Chain 5 UniProt (TrEMBL) Primary ID of Target Chain 5 UniProt (TrEMBL) Secondary ID(s) of Target Chain 5 UniProt (TrEMBL) Alternative ID(s) of Target Chain 5 BindingDB Target Chain Sequence 6 PDB ID(s) of Target Chain 6 UniProt (SwissProt) Recommended Name of Target Chain 6 UniProt (SwissProt) Entry Name of Target Chain 6 UniProt (SwissProt) Primary ID of Target Chain 6 UniProt (SwissProt) Secondary ID(s) of Target Chain 6 UniProt (SwissProt) Alternative ID(s) of Target Chain 6 UniProt (TrEMBL) Submitted Name of Target Chain 6 UniProt (TrEMBL) Entry Name of Target Chain 6 UniProt (TrEMBL) Primary ID of Target Chain 6 UniProt (TrEMBL) Secondary ID(s) of Target Chain 6 UniProt (TrEMBL) Alternative ID(s) of Target Chain 6 BindingDB Target Chain Sequence 7 PDB ID(s) of Target Chain 7 UniProt (SwissProt) Recommended Name of Target Chain 7 UniProt (SwissProt) Entry Name of Target Chain 7 UniProt (SwissProt) Primary ID of Target Chain 7 UniProt (SwissProt) Secondary ID(s) of Target Chain 7 UniProt (SwissProt) Alternative ID(s) of Target Chain 7 UniProt (TrEMBL) Submitted Name of Target Chain 7 UniProt (TrEMBL) Entry Name of Target Chain 7 UniProt (TrEMBL) Primary ID of Target Chain 7 UniProt (TrEMBL) Secondary ID(s) of Target Chain 7 UniProt (TrEMBL) Alternative ID(s) of Target Chain 7 BindingDB Target Chain Sequence 8 PDB ID(s) of Target Chain 8 UniProt (SwissProt) Recommended Name of Target Chain 8 UniProt (SwissProt) Entry Name of Target Chain 8 UniProt (SwissProt) Primary ID of Target Chain 8 UniProt (SwissProt) Secondary ID(s) of Target Chain 8 UniProt (SwissProt) Alternative ID(s) of Target Chain 8 UniProt (TrEMBL) Submitted Name of Target Chain 8 UniProt (TrEMBL) Entry Name of Target Chain 8 UniProt (TrEMBL) Primary ID of Target Chain 8 UniProt (TrEMBL) Secondary ID(s) of Target Chain 8 UniProt (TrEMBL) Alternative ID(s) of Target Chain 8 BindingDB Target Chain Sequence 9 PDB ID(s) of Target Chain 9 UniProt (SwissProt) Recommended Name of Target Chain 9 UniProt (SwissProt) Entry Name of Target Chain 9 UniProt (SwissProt) Primary ID of Target Chain 9 UniProt (SwissProt) Secondary ID(s) of Target Chain 9 UniProt (SwissProt) Alternative ID(s) of Target Chain 9 UniProt (TrEMBL) Submitted Name of Target Chain 9 UniProt (TrEMBL) Entry Name of Target Chain 9 UniProt (TrEMBL) Primary ID of Target Chain 9 UniProt (TrEMBL) Secondary ID(s) of Target Chain 9 UniProt (TrEMBL) Alternative ID(s) of Target Chain 9 BindingDB Target Chain Sequence 10 PDB ID(s) of Target Chain 10 UniProt (SwissProt) Recommended Name of Target Chain 10 UniProt (SwissProt) Entry Name of Target Chain 10 UniProt (SwissProt) Primary ID of Target Chain 10 UniProt (SwissProt) Secondary ID(s) of Target Chain 10 UniProt (SwissProt) Alternative ID(s) of Target Chain 10 UniProt (TrEMBL) Submitted Name of Target Chain 10 UniProt (TrEMBL) Entry Name of Target Chain 10 UniProt (TrEMBL) Primary ID of Target Chain 10 UniProt (TrEMBL) Secondary ID(s) of Target Chain 10 UniProt (TrEMBL) Alternative ID(s) of Target Chain 10 BindingDB Target Chain Sequence 11 PDB ID(s) of Target Chain 11 UniProt (SwissProt) Recommended Name of Target Chain 11 UniProt (SwissProt) Entry Name of Target Chain 11 UniProt (SwissProt) Primary ID of Target Chain 11 UniProt (SwissProt) Secondary ID(s) of Target Chain 11 UniProt (SwissProt) Alternative ID(s) of Target Chain 11 UniProt (TrEMBL) Submitted Name of Target Chain 11 UniProt (TrEMBL) Entry Name of Target Chain 11 UniProt (TrEMBL) Primary ID of Target Chain 11 UniProt (TrEMBL) Secondary ID(s) of Target Chain 11 UniProt (TrEMBL) Alternative ID(s) of Target Chain 11 BindingDB Target Chain Sequence 12 PDB ID(s) of Target Chain 12 UniProt (SwissProt) Recommended Name of Target Chain 12 UniProt (SwissProt) Entry Name of Target Chain 12 UniProt (SwissProt) Primary ID of Target Chain 12 UniProt (SwissProt) Secondary ID(s) of Target Chain 12 UniProt (SwissProt) Alternative ID(s) of Target Chain 12 UniProt (TrEMBL) Submitted Name of Target Chain 12 UniProt (TrEMBL) Entry Name of Target Chain 12 UniProt (TrEMBL) Primary ID of Target Chain 12 UniProt (TrEMBL) Secondary ID(s) of Target Chain 12 UniProt (TrEMBL) Alternative ID(s) of Target Chain 12 BindingDB Target Chain Sequence 13 PDB ID(s) of Target Chain 13 UniProt (SwissProt) Recommended Name of Target Chain 13 UniProt (SwissProt) Entry Name of Target Chain 13 UniProt (SwissProt) Primary ID of Target Chain 13 UniProt (SwissProt) Secondary ID(s) of Target Chain 13 UniProt (SwissProt) Alternative ID(s) of Target Chain 13 UniProt (TrEMBL) Submitted Name of Target Chain 13 UniProt (TrEMBL) Entry Name of Target Chain 13 UniProt (TrEMBL) Primary ID of Target Chain 13 UniProt (TrEMBL) Secondary ID(s) of Target Chain 13 UniProt (TrEMBL) Alternative ID(s) of Target Chain 13 BindingDB Target Chain Sequence 14 PDB ID(s) of Target Chain 14 UniProt (SwissProt) Recommended Name of Target Chain 14 UniProt (SwissProt) Entry Name of Target Chain 14 UniProt (SwissProt) Primary ID of Target Chain 14 UniProt (SwissProt) Secondary ID(s) of Target Chain 14 UniProt (SwissProt) Alternative ID(s) of Target Chain 14 UniProt (TrEMBL) Submitted Name of Target Chain 14 UniProt (TrEMBL) Entry Name of Target Chain 14 UniProt (TrEMBL) Primary ID of Target Chain 14 UniProt (TrEMBL) Secondary ID(s) of Target Chain 14 UniProt (TrEMBL) Alternative ID(s) of Target Chain 14 BindingDB Target Chain Sequence 15 PDB ID(s) of Target Chain 15 UniProt (SwissProt) Recommended Name of Target Chain 15 UniProt (SwissProt) Entry Name of Target Chain 15 UniProt (SwissProt) Primary ID of Target Chain 15 UniProt (SwissProt) Secondary ID(s) of Target Chain 15 UniProt (SwissProt) Alternative ID(s) of Target Chain 15 UniProt (TrEMBL) Submitted Name of Target Chain 15 UniProt (TrEMBL) Entry Name of Target Chain 15 UniProt (TrEMBL) Primary ID of Target Chain 15 UniProt (TrEMBL) Secondary ID(s) of Target Chain 15 UniProt (TrEMBL) Alternative ID(s) of Target Chain 15 BindingDB Target Chain Sequence 16 PDB ID(s) of Target Chain 16 UniProt (SwissProt) Recommended Name of Target Chain 16 UniProt (SwissProt) Entry Name of Target Chain 16 UniProt (SwissProt) Primary ID of Target Chain 16 UniProt (SwissProt) Secondary ID(s) of Target Chain 16 UniProt (SwissProt) Alternative ID(s) of Target Chain 16 UniProt (TrEMBL) Submitted Name of Target Chain 16 UniProt (TrEMBL) Entry Name of Target Chain 16 UniProt (TrEMBL) Primary ID of Target Chain 16 UniProt (TrEMBL) Secondary ID(s) of Target Chain 16 UniProt (TrEMBL) Alternative ID(s) of Target Chain 16 BindingDB Target Chain Sequence 17 PDB ID(s) of Target Chain 17 UniProt (SwissProt) Recommended Name of Target Chain 17 UniProt (SwissProt) Entry Name of Target Chain 17 UniProt (SwissProt) Primary ID of Target Chain 17 UniProt (SwissProt) Secondary ID(s) of Target Chain 17 UniProt (SwissProt) Alternative ID(s) of Target Chain 17 UniProt (TrEMBL) Submitted Name of Target Chain 17 UniProt (TrEMBL) Entry Name of Target Chain 17 UniProt (TrEMBL) Primary ID of Target Chain 17 UniProt (TrEMBL) Secondary ID(s) of Target Chain 17 UniProt (TrEMBL) Alternative ID(s) of Target Chain 17 BindingDB Target Chain Sequence 18 PDB ID(s) of Target Chain 18 UniProt (SwissProt) Recommended Name of Target Chain 18 UniProt (SwissProt) Entry Name of Target Chain 18 UniProt (SwissProt) Primary ID of Target Chain 18 UniProt (SwissProt) Secondary ID(s) of Target Chain 18 UniProt (SwissProt) Alternative ID(s) of Target Chain 18 UniProt (TrEMBL) Submitted Name of Target Chain 18 UniProt (TrEMBL) Entry Name of Target Chain 18 UniProt (TrEMBL) Primary ID of Target Chain 18 UniProt (TrEMBL) Secondary ID(s) of Target Chain 18 UniProt (TrEMBL) Alternative ID(s) of Target Chain 18 BindingDB Target Chain Sequence 19 PDB ID(s) of Target Chain 19 UniProt (SwissProt) Recommended Name of Target Chain 19 UniProt (SwissProt) Entry Name of Target Chain 19 UniProt (SwissProt) Primary ID of Target Chain 19 UniProt (SwissProt) Secondary ID(s) of Target Chain 19 UniProt (SwissProt) Alternative ID(s) of Target Chain 19 UniProt (TrEMBL) Submitted Name of Target Chain 19 UniProt (TrEMBL) Entry Name of Target Chain 19 UniProt (TrEMBL) Primary ID of Target Chain 19 UniProt (TrEMBL) Secondary ID(s) of Target Chain 19 UniProt (TrEMBL) Alternative ID(s) of Target Chain 19 BindingDB Target Chain Sequence 20 PDB ID(s) of Target Chain 20 UniProt (SwissProt) Recommended Name of Target Chain 20 UniProt (SwissProt) Entry Name of Target Chain 20 UniProt (SwissProt) Primary ID of Target Chain 20 UniProt (SwissProt) Secondary ID(s) of Target Chain 20 UniProt (SwissProt) Alternative ID(s) of Target Chain 20 UniProt (TrEMBL) Submitted Name of Target Chain 20 UniProt (TrEMBL) Entry Name of Target Chain 20 UniProt (TrEMBL) Primary ID of Target Chain 20 UniProt (TrEMBL) Secondary ID(s) of Target Chain 20 UniProt (TrEMBL) Alternative ID(s) of Target Chain 20 BindingDB Target Chain Sequence 21 PDB ID(s) of Target Chain 21 UniProt (SwissProt) Recommended Name of Target Chain 21 UniProt (SwissProt) Entry Name of Target Chain 21 UniProt (SwissProt) Primary ID of Target Chain 21 UniProt (SwissProt) Secondary ID(s) of Target Chain 21 UniProt (SwissProt) Alternative ID(s) of Target Chain 21 UniProt (TrEMBL) Submitted Name of Target Chain 21 UniProt (TrEMBL) Entry Name of Target Chain 21 UniProt (TrEMBL) Primary ID of Target Chain 21 UniProt (TrEMBL) Secondary ID(s) of Target Chain 21 UniProt (TrEMBL) Alternative ID(s) of Target Chain 21 BindingDB Target Chain Sequence 22 PDB ID(s) of Target Chain 22 UniProt (SwissProt) Recommended Name of Target Chain 22 UniProt (SwissProt) Entry Name of Target Chain 22 UniProt (SwissProt) Primary ID of Target Chain 22 UniProt (SwissProt) Secondary ID(s) of Target Chain 22 UniProt (SwissProt) Alternative ID(s) of Target Chain 22 UniProt (TrEMBL) Submitted Name of Target Chain 22 UniProt (TrEMBL) Entry Name of Target Chain 22 UniProt (TrEMBL) Primary ID of Target Chain 22 UniProt (TrEMBL) Secondary ID(s) of Target Chain 22 UniProt (TrEMBL) Alternative ID(s) of Target Chain 22 BindingDB Target Chain Sequence 23 PDB ID(s) of Target Chain 23 UniProt (SwissProt) Recommended Name of Target Chain 23 UniProt (SwissProt) Entry Name of Target Chain 23 UniProt (SwissProt) Primary ID of Target Chain 23 UniProt (SwissProt) Secondary ID(s) of Target Chain 23 UniProt (SwissProt) Alternative ID(s) of Target Chain 23 UniProt (TrEMBL) Submitted Name of Target Chain 23 UniProt (TrEMBL) Entry Name of Target Chain 23 UniProt (TrEMBL) Primary ID of Target Chain 23 UniProt (TrEMBL) Secondary ID(s) of Target Chain 23 UniProt (TrEMBL) Alternative ID(s) of Target Chain 23 BindingDB Target Chain Sequence 24 PDB ID(s) of Target Chain 24 UniProt (SwissProt) Recommended Name of Target Chain 24 UniProt (SwissProt) Entry Name of Target Chain 24 UniProt (SwissProt) Primary ID of Target Chain 24 UniProt (SwissProt) Secondary ID(s) of Target Chain 24 UniProt (SwissProt) Alternative ID(s) of Target Chain 24 UniProt (TrEMBL) Submitted Name of Target Chain 24 UniProt (TrEMBL) Entry Name of Target Chain 24 UniProt (TrEMBL) Primary ID of Target Chain 24 UniProt (TrEMBL) Secondary ID(s) of Target Chain 24 UniProt (TrEMBL) Alternative ID(s) of Target Chain 24 BindingDB Target Chain Sequence 25 PDB ID(s) of Target Chain 25 UniProt (SwissProt) Recommended Name of Target Chain 25 UniProt (SwissProt) Entry Name of Target Chain 25 UniProt (SwissProt) Primary ID of Target Chain 25 UniProt (SwissProt) Secondary ID(s) of Target Chain 25 UniProt (SwissProt) Alternative ID(s) of Target Chain 25 UniProt (TrEMBL) Submitted Name of Target Chain 25 UniProt (TrEMBL) Entry Name of Target Chain 25 UniProt (TrEMBL) Primary ID of Target Chain 25 UniProt (TrEMBL) Secondary ID(s) of Target Chain 25 UniProt (TrEMBL) Alternative ID(s) of Target Chain 25 BindingDB Target Chain Sequence 26 PDB ID(s) of Target Chain 26 UniProt (SwissProt) Recommended Name of Target Chain 26 UniProt (SwissProt) Entry Name of Target Chain 26 UniProt (SwissProt) Primary ID of Target Chain 26 UniProt (SwissProt) Secondary ID(s) of Target Chain 26 UniProt (SwissProt) Alternative ID(s) of Target Chain 26 UniProt (TrEMBL) Submitted Name of Target Chain 26 UniProt (TrEMBL) Entry Name of Target Chain 26 UniProt (TrEMBL) Primary ID of Target Chain 26 UniProt (TrEMBL) Secondary ID(s) of Target Chain 26 UniProt (TrEMBL) Alternative ID(s) of Target Chain 26 BindingDB Target Chain Sequence 27 PDB ID(s) of Target Chain 27 UniProt (SwissProt) Recommended Name of Target Chain 27 UniProt (SwissProt) Entry Name of Target Chain 27 UniProt (SwissProt) Primary ID of Target Chain 27 UniProt (SwissProt) Secondary ID(s) of Target Chain 27 UniProt (SwissProt) Alternative ID(s) of Target Chain 27 UniProt (TrEMBL) Submitted Name of Target Chain 27 UniProt (TrEMBL) Entry Name of Target Chain 27 UniProt (TrEMBL) Primary ID of Target Chain 27 UniProt (TrEMBL) Secondary ID(s) of Target Chain 27 UniProt (TrEMBL) Alternative ID(s) of Target Chain 27 BindingDB Target Chain Sequence 28 PDB ID(s) of Target Chain 28 UniProt (SwissProt) Recommended Name of Target Chain 28 UniProt (SwissProt) Entry Name of Target Chain 28 UniProt (SwissProt) Primary ID of Target Chain 28 UniProt (SwissProt) Secondary ID(s) of Target Chain 28 UniProt (SwissProt) Alternative ID(s) of Target Chain 28 UniProt (TrEMBL) Submitted Name of Target Chain 28 UniProt (TrEMBL) Entry Name of Target Chain 28 UniProt (TrEMBL) Primary ID of Target Chain 28 UniProt (TrEMBL) Secondary ID(s) of Target Chain 28 UniProt (TrEMBL) Alternative ID(s) of Target Chain 28 BindingDB Target Chain Sequence 29 PDB ID(s) of Target Chain 29 UniProt (SwissProt) Recommended Name of Target Chain 29 UniProt (SwissProt) Entry Name of Target Chain 29 UniProt (SwissProt) Primary ID of Target Chain 29 UniProt (SwissProt) Secondary ID(s) of Target Chain 29 UniProt (SwissProt) Alternative ID(s) of Target Chain 29 UniProt (TrEMBL) Submitted Name of Target Chain 29 UniProt (TrEMBL) Entry Name of Target Chain 29 UniProt (TrEMBL) Primary ID of Target Chain 29 UniProt (TrEMBL) Secondary ID(s) of Target Chain 29 UniProt (TrEMBL) Alternative ID(s) of Target Chain 29 BindingDB Target Chain Sequence 30 PDB ID(s) of Target Chain 30 UniProt (SwissProt) Recommended Name of Target Chain 30 UniProt (SwissProt) Entry Name of Target Chain 30 UniProt (SwissProt) Primary ID of Target Chain 30 UniProt (SwissProt) Secondary ID(s) of Target Chain 30 UniProt (SwissProt) Alternative ID(s) of Target Chain 30 UniProt (TrEMBL) Submitted Name of Target Chain 30 UniProt (TrEMBL) Entry Name of Target Chain 30 UniProt (TrEMBL) Primary ID of Target Chain 30 UniProt (TrEMBL) Secondary ID(s) of Target Chain 30 UniProt (TrEMBL) Alternative ID(s) of Target Chain 30 BindingDB Target Chain Sequence 31 PDB ID(s) of Target Chain 31 UniProt (SwissProt) Recommended Name of Target Chain 31 UniProt (SwissProt) Entry Name of Target Chain 31 UniProt (SwissProt) Primary ID of Target Chain 31 UniProt (SwissProt) Secondary ID(s) of Target Chain 31 UniProt (SwissProt) Alternative ID(s) of Target Chain 31 UniProt (TrEMBL) Submitted Name of Target Chain 31 UniProt (TrEMBL) Entry Name of Target Chain 31 UniProt (TrEMBL) Primary ID of Target Chain 31 UniProt (TrEMBL) Secondary ID(s) of Target Chain 31 UniProt (TrEMBL) Alternative ID(s) of Target Chain 31 BindingDB Target Chain Sequence 32 PDB ID(s) of Target Chain 32 UniProt (SwissProt) Recommended Name of Target Chain 32 UniProt (SwissProt) Entry Name of Target Chain 32 UniProt (SwissProt) Primary ID of Target Chain 32 UniProt (SwissProt) Secondary ID(s) of Target Chain 32 UniProt (SwissProt) Alternative ID(s) of Target Chain 32 UniProt (TrEMBL) Submitted Name of Target Chain 32 UniProt (TrEMBL) Entry Name of Target Chain 32 UniProt (TrEMBL) Primary ID of Target Chain 32 UniProt (TrEMBL) Secondary ID(s) of Target Chain 32 UniProt (TrEMBL) Alternative ID(s) of Target Chain 32 BindingDB Target Chain Sequence 33 PDB ID(s) of Target Chain 33 UniProt (SwissProt) Recommended Name of Target Chain 33 UniProt (SwissProt) Entry Name of Target Chain 33 UniProt (SwissProt) Primary ID of Target Chain 33 UniProt (SwissProt) Secondary ID(s) of Target Chain 33 UniProt (SwissProt) Alternative ID(s) of Target Chain 33 UniProt (TrEMBL) Submitted Name of Target Chain 33 UniProt (TrEMBL) Entry Name of Target Chain 33 UniProt (TrEMBL) Primary ID of Target Chain 33 UniProt (TrEMBL) Secondary ID(s) of Target Chain 33 UniProt (TrEMBL) Alternative ID(s) of Target Chain 33 BindingDB Target Chain Sequence 34 PDB ID(s) of Target Chain 34 UniProt (SwissProt) Recommended Name of Target Chain 34 UniProt (SwissProt) Entry Name of Target Chain 34 UniProt (SwissProt) Primary ID of Target Chain 34 UniProt (SwissProt) Secondary ID(s) of Target Chain 34 UniProt (SwissProt) Alternative ID(s) of Target Chain 34 UniProt (TrEMBL) Submitted Name of Target Chain 34 UniProt (TrEMBL) Entry Name of Target Chain 34 UniProt (TrEMBL) Primary ID of Target Chain 34 UniProt (TrEMBL) Secondary ID(s) of Target Chain 34 UniProt (TrEMBL) Alternative ID(s) of Target Chain 34 BindingDB Target Chain Sequence 35 PDB ID(s) of Target Chain 35 UniProt (SwissProt) Recommended Name of Target Chain 35 UniProt (SwissProt) Entry Name of Target Chain 35 UniProt (SwissProt) Primary ID of Target Chain 35 UniProt (SwissProt) Secondary ID(s) of Target Chain 35 UniProt (SwissProt) Alternative ID(s) of Target Chain 35 UniProt (TrEMBL) Submitted Name of Target Chain 35 UniProt (TrEMBL) Entry Name of Target Chain 35 UniProt (TrEMBL) Primary ID of Target Chain 35 UniProt (TrEMBL) Secondary ID(s) of Target Chain 35 UniProt (TrEMBL) Alternative ID(s) of Target Chain 35 BindingDB Target Chain Sequence 36 PDB ID(s) of Target Chain 36 UniProt (SwissProt) Recommended Name of Target Chain 36 UniProt (SwissProt) Entry Name of Target Chain 36 UniProt (SwissProt) Primary ID of Target Chain 36 UniProt (SwissProt) Secondary ID(s) of Target Chain 36 UniProt (SwissProt) Alternative ID(s) of Target Chain 36 UniProt (TrEMBL) Submitted Name of Target Chain 36 UniProt (TrEMBL) Entry Name of Target Chain 36 UniProt (TrEMBL) Primary ID of Target Chain 36 UniProt (TrEMBL) Secondary ID(s) of Target Chain 36 UniProt (TrEMBL) Alternative ID(s) of Target Chain 36 BindingDB Target Chain Sequence 37 PDB ID(s) of Target Chain 37 UniProt (SwissProt) Recommended Name of Target Chain 37 UniProt (SwissProt) Entry Name of Target Chain 37 UniProt (SwissProt) Primary ID of Target Chain 37 UniProt (SwissProt) Secondary ID(s) of Target Chain 37 UniProt (SwissProt) Alternative ID(s) of Target Chain 37 UniProt (TrEMBL) Submitted Name of Target Chain 37 UniProt (TrEMBL) Entry Name of Target Chain 37 UniProt (TrEMBL) Primary ID of Target Chain 37 UniProt (TrEMBL) Secondary ID(s) of Target Chain 37 UniProt (TrEMBL) Alternative ID(s) of Target Chain 37 BindingDB Target Chain Sequence 38 PDB ID(s) of Target Chain 38 UniProt (SwissProt) Recommended Name of Target Chain 38 UniProt (SwissProt) Entry Name of Target Chain 38 UniProt (SwissProt) Primary ID of Target Chain 38 UniProt (SwissProt) Secondary ID(s) of Target Chain 38 UniProt (SwissProt) Alternative ID(s) of Target Chain 38 UniProt (TrEMBL) Submitted Name of Target Chain 38 UniProt (TrEMBL) Entry Name of Target Chain 38 UniProt (TrEMBL) Primary ID of Target Chain 38 UniProt (TrEMBL) Secondary ID(s) of Target Chain 38 UniProt (TrEMBL) Alternative ID(s) of Target Chain 38 BindingDB Target Chain Sequence 39 PDB ID(s) of Target Chain 39 UniProt (SwissProt) Recommended Name of Target Chain 39 UniProt (SwissProt) Entry Name of Target Chain 39 UniProt (SwissProt) Primary ID of Target Chain 39 UniProt (SwissProt) Secondary ID(s) of Target Chain 39 UniProt (SwissProt) Alternative ID(s) of Target Chain 39 UniProt (TrEMBL) Submitted Name of Target Chain 39 UniProt (TrEMBL) Entry Name of Target Chain 39 UniProt (TrEMBL) Primary ID of Target Chain 39 UniProt (TrEMBL) Secondary ID(s) of Target Chain 39 UniProt (TrEMBL) Alternative ID(s) of Target Chain 39 BindingDB Target Chain Sequence 40 PDB ID(s) of Target Chain 40 UniProt (SwissProt) Recommended Name of Target Chain 40 UniProt (SwissProt) Entry Name of Target Chain 40 UniProt (SwissProt) Primary ID of Target Chain 40 UniProt (SwissProt) Secondary ID(s) of Target Chain 40 UniProt (SwissProt) Alternative ID(s) of Target Chain 40 UniProt (TrEMBL) Submitted Name of Target Chain 40 UniProt (TrEMBL) Entry Name of Target Chain 40 UniProt (TrEMBL) Primary ID of Target Chain 40 UniProt (TrEMBL) Secondary ID(s) of Target Chain 40 UniProt (TrEMBL) Alternative ID(s) of Target Chain 40 BindingDB Target Chain Sequence 41 PDB ID(s) of Target Chain 41 UniProt (SwissProt) Recommended Name of Target Chain 41 UniProt (SwissProt) Entry Name of Target Chain 41 UniProt (SwissProt) Primary ID of Target Chain 41 UniProt (SwissProt) Secondary ID(s) of Target Chain 41 UniProt (SwissProt) Alternative ID(s) of Target Chain 41 UniProt (TrEMBL) Submitted Name of Target Chain 41 UniProt (TrEMBL) Entry Name of Target Chain 41 UniProt (TrEMBL) Primary ID of Target Chain 41 UniProt (TrEMBL) Secondary ID(s) of Target Chain 41 UniProt (TrEMBL) Alternative ID(s) of Target Chain 41 BindingDB Target Chain Sequence 42 PDB ID(s) of Target Chain 42 UniProt (SwissProt) Recommended Name of Target Chain 42 UniProt (SwissProt) Entry Name of Target Chain 42 UniProt (SwissProt) Primary ID of Target Chain 42 UniProt (SwissProt) Secondary ID(s) of Target Chain 42 UniProt (SwissProt) Alternative ID(s) of Target Chain 42 UniProt (TrEMBL) Submitted Name of Target Chain 42 UniProt (TrEMBL) Entry Name of Target Chain 42 UniProt (TrEMBL) Primary ID of Target Chain 42 UniProt (TrEMBL) Secondary ID(s) of Target Chain 42 UniProt (TrEMBL) Alternative ID(s) of Target Chain 42 BindingDB Target Chain Sequence 43 PDB ID(s) of Target Chain 43 UniProt (SwissProt) Recommended Name of Target Chain 43 UniProt (SwissProt) Entry Name of Target Chain 43 UniProt (SwissProt) Primary ID of Target Chain 43 UniProt (SwissProt) Secondary ID(s) of Target Chain 43 UniProt (SwissProt) Alternative ID(s) of Target Chain 43 UniProt (TrEMBL) Submitted Name of Target Chain 43 UniProt (TrEMBL) Entry Name of Target Chain 43 UniProt (TrEMBL) Primary ID of Target Chain 43 UniProt (TrEMBL) Secondary ID(s) of Target Chain 43 UniProt (TrEMBL) Alternative ID(s) of Target Chain 43 BindingDB Target Chain Sequence 44 PDB ID(s) of Target Chain 44 UniProt (SwissProt) Recommended Name of Target Chain 44 UniProt (SwissProt) Entry Name of Target Chain 44 UniProt (SwissProt) Primary ID of Target Chain 44 UniProt (SwissProt) Secondary ID(s) of Target Chain 44 UniProt (SwissProt) Alternative ID(s) of Target Chain 44 UniProt (TrEMBL) Submitted Name of Target Chain 44 UniProt (TrEMBL) Entry Name of Target Chain 44 UniProt (TrEMBL) Primary ID of Target Chain 44 UniProt (TrEMBL) Secondary ID(s) of Target Chain 44 UniProt (TrEMBL) Alternative ID(s) of Target Chain 44 BindingDB Target Chain Sequence 45 PDB ID(s) of Target Chain 45 UniProt (SwissProt) Recommended Name of Target Chain 45 UniProt (SwissProt) Entry Name of Target Chain 45 UniProt (SwissProt) Primary ID of Target Chain 45 UniProt (SwissProt) Secondary ID(s) of Target Chain 45 UniProt (SwissProt) Alternative ID(s) of Target Chain 45 UniProt (TrEMBL) Submitted Name of Target Chain 45 UniProt (TrEMBL) Entry Name of Target Chain 45 UniProt (TrEMBL) Primary ID of Target Chain 45 UniProt (TrEMBL) Secondary ID(s) of Target Chain 45 UniProt (TrEMBL) Alternative ID(s) of Target Chain 45 BindingDB Target Chain Sequence 46 PDB ID(s) of Target Chain 46 UniProt (SwissProt) Recommended Name of Target Chain 46 UniProt (SwissProt) Entry Name of Target Chain 46 UniProt (SwissProt) Primary ID of Target Chain 46 UniProt (SwissProt) Secondary ID(s) of Target Chain 46 UniProt (SwissProt) Alternative ID(s) of Target Chain 46 UniProt (TrEMBL) Submitted Name of Target Chain 46 UniProt (TrEMBL) Entry Name of Target Chain 46 UniProt (TrEMBL) Primary ID of Target Chain 46 UniProt (TrEMBL) Secondary ID(s) of Target Chain 46 UniProt (TrEMBL) Alternative ID(s) of Target Chain 46 BindingDB Target Chain Sequence 47 PDB ID(s) of Target Chain 47 UniProt (SwissProt) Recommended Name of Target Chain 47 UniProt (SwissProt) Entry Name of Target Chain 47 UniProt (SwissProt) Primary ID of Target Chain 47 UniProt (SwissProt) Secondary ID(s) of Target Chain 47 UniProt (SwissProt) Alternative ID(s) of Target Chain 47 UniProt (TrEMBL) Submitted Name of Target Chain 47 UniProt (TrEMBL) Entry Name of Target Chain 47 UniProt (TrEMBL) Primary ID of Target Chain 47 UniProt (TrEMBL) Secondary ID(s) of Target Chain 47 UniProt (TrEMBL) Alternative ID(s) of Target Chain 47 BindingDB Target Chain Sequence 48 PDB ID(s) of Target Chain 48 UniProt (SwissProt) Recommended Name of Target Chain 48 UniProt (SwissProt) Entry Name of Target Chain 48 UniProt (SwissProt) Primary ID of Target Chain 48 UniProt (SwissProt) Secondary ID(s) of Target Chain 48 UniProt (SwissProt) Alternative ID(s) of Target Chain 48 UniProt (TrEMBL) Submitted Name of Target Chain 48 UniProt (TrEMBL) Entry Name of Target Chain 48 UniProt (TrEMBL) Primary ID of Target Chain 48 UniProt (TrEMBL) Secondary ID(s) of Target Chain 48 UniProt (TrEMBL) Alternative ID(s) of Target Chain 48 BindingDB Target Chain Sequence 49 PDB ID(s) of Target Chain 49 UniProt (SwissProt) Recommended Name of Target Chain 49 UniProt (SwissProt) Entry Name of Target Chain 49 UniProt (SwissProt) Primary ID of Target Chain 49 UniProt (SwissProt) Secondary ID(s) of Target Chain 49 UniProt (SwissProt) Alternative ID(s) of Target Chain 49 UniProt (TrEMBL) Submitted Name of Target Chain 49 UniProt (TrEMBL) Entry Name of Target Chain 49 UniProt (TrEMBL) Primary ID of Target Chain 49 UniProt (TrEMBL) Secondary ID(s) of Target Chain 49 UniProt (TrEMBL) Alternative ID(s) of Target Chain 49 BindingDB Target Chain Sequence 50 PDB ID(s) of Target Chain 50 UniProt (SwissProt) Recommended Name of Target Chain 50 UniProt (SwissProt) Entry Name of Target Chain 50 UniProt (SwissProt) Primary ID of Target Chain 50 UniProt (SwissProt) Secondary ID(s) of Target Chain 50 UniProt (SwissProt) Alternative ID(s) of Target Chain 50 UniProt (TrEMBL) Submitted Name of Target Chain 50 UniProt (TrEMBL) Entry Name of Target Chain 50 UniProt (TrEMBL) Primary ID of Target Chain 50 UniProt (TrEMBL) Secondary ID(s) of Target Chain 50 UniProt (TrEMBL) Alternative ID(s) of Target Chain 50 1073000 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cc(OC)cc(OC)c1 InChI=1S/C28H30N4O5/c1-35-19-26-25(28(34)29-15-22-12-23(36-2)14-24(13-22)37-3)18-32(30-26)17-21-9-7-20(8-10-21)16-31-11-5-4-6-27(31)33/h4-14,18H,15-17,19H2,1-3H3,(H,29,34) BKELALJCIHUNCS-UHFFFAOYSA-N 408665 N-(3,5-Dimethoxybenzyl)-3-(methoxymethyl)-1-(4-((2-oxopyridin-1(2H)-yl)methyl)benzyl)-1H-pyrazole-4-carboxamide::US10364238, Example 1::US11001578, Example 1::US11084809, Example 1::US11198691, Example 1 Plasma kallikrein Human 698 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408665 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408665&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121364994 406799299 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073001 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cc(OC)cc(OC)c1 InChI=1S/C28H30N4O5/c1-35-19-26-25(28(34)29-15-22-12-23(36-2)14-24(13-22)37-3)18-32(30-26)17-21-9-7-20(8-10-21)16-31-11-5-4-6-27(31)33/h4-14,18H,15-17,19H2,1-3H3,(H,29,34) BKELALJCIHUNCS-UHFFFAOYSA-N 408665 N-(3,5-Dimethoxybenzyl)-3-(methoxymethyl)-1-(4-((2-oxopyridin-1(2H)-yl)methyl)benzyl)-1H-pyrazole-4-carboxamide::US10364238, Example 1::US11001578, Example 1::US11084809, Example 1::US11198691, Example 1 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408665 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408665&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121364994 406799299 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073002 COc1cccc(CNC(=O)c2cn(Cc3ccc(Cn4ccccc4=O)cc3)nc2N)c1F InChI=1S/C25H24FN5O3/c1-34-21-6-4-5-19(23(21)26)13-28-25(33)20-16-31(29-24(20)27)15-18-10-8-17(9-11-18)14-30-12-3-2-7-22(30)32/h2-12,16H,13-15H2,1H3,(H2,27,29)(H,28,33) HICYNMRHZGAFMT-UHFFFAOYSA-N 408666 3-Amino-1-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid 2-fluoro-3-methoxy-benzylamide::US10364238, Example 2::US11001578, Example 2::US11084809, Example 2::US11198691, Example 2 Plasma kallikrein Human 8.70 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408666 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408666&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365045 406799300 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073003 COc1cccc(CNC(=O)c2cn(Cc3ccc(Cn4ccccc4=O)cc3)nc2N)c1F InChI=1S/C25H24FN5O3/c1-34-21-6-4-5-19(23(21)26)13-28-25(33)20-16-31(29-24(20)27)15-18-10-8-17(9-11-18)14-30-12-3-2-7-22(30)32/h2-12,16H,13-15H2,1H3,(H2,27,29)(H,28,33) HICYNMRHZGAFMT-UHFFFAOYSA-N 408666 3-Amino-1-[4-(2-oxo-2H-pyridin-1-ylmethyl)-benzyl]-1H-pyrazole-4-carboxylic acid 2-fluoro-3-methoxy-benzylamide::US10364238, Example 2::US11001578, Example 2::US11084809, Example 2::US11198691, Example 2 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408666 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408666&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365045 406799300 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073004 COCc1nn(Cc2cnc3cc(Cl)ccc3c2)cc1C(=O)NCc1cccc(OC)c1F InChI=1S/C24H22ClFN4O3/c1-32-14-21-19(24(31)28-11-17-4-3-5-22(33-2)23(17)26)13-30(29-21)12-15-8-16-6-7-18(25)9-20(16)27-10-15/h3-10,13H,11-12,14H2,1-2H3,(H,28,31) WPIUJKAYUGBTDW-UHFFFAOYSA-N 408667 1-(7-Chloro-quinolin-3-ylmethyl)-3-methoxymethyl-1H-pyrazole-4-carboxylic acid 2-fluoro-3-methoxy-benzylamide::US10364238, Example 3::US11001578, Example 3::US11084809, Example 3::US11198691, Example 3 Plasma kallikrein Human 2580 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408667 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408667&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365013 406799301 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073005 COCc1nn(Cc2cnc3cc(Cl)ccc3c2)cc1C(=O)NCc1cccc(OC)c1F InChI=1S/C24H22ClFN4O3/c1-32-14-21-19(24(31)28-11-17-4-3-5-22(33-2)23(17)26)13-30(29-21)12-15-8-16-6-7-18(25)9-20(16)27-10-15/h3-10,13H,11-12,14H2,1-2H3,(H,28,31) WPIUJKAYUGBTDW-UHFFFAOYSA-N 408667 1-(7-Chloro-quinolin-3-ylmethyl)-3-methoxymethyl-1H-pyrazole-4-carboxylic acid 2-fluoro-3-methoxy-benzylamide::US10364238, Example 3::US11001578, Example 3::US11084809, Example 3::US11198691, Example 3 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408667 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408667&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365013 406799301 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073006 COc1cccc(CNC(=O)c2cn(Cc3ccc(Cn4cc(C)cn4)cc3)nc2C(F)(F)F)c1F InChI=1S/C25H23F4N5O2/c1-16-10-31-33(12-16)13-17-6-8-18(9-7-17)14-34-15-20(23(32-34)25(27,28)29)24(35)30-11-19-4-3-5-21(36-2)22(19)26/h3-10,12,15H,11,13-14H2,1-2H3,(H,30,35) QZMZZOCEJPCAIJ-UHFFFAOYSA-N 408668 N-[(2-fluoro-3-methoxyphenyl)methyl]-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide::US10364238, Example 4::US11001578, Example 4::US11084809, Example 4::US11198691, Example 4 Plasma kallikrein Human 136 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408668 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408668&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365107 406799302 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073007 COc1cccc(CNC(=O)c2cn(Cc3ccc(Cn4cc(C)cn4)cc3)nc2C(F)(F)F)c1F InChI=1S/C25H23F4N5O2/c1-16-10-31-33(12-16)13-17-6-8-18(9-7-17)14-34-15-20(23(32-34)25(27,28)29)24(35)30-11-19-4-3-5-21(36-2)22(19)26/h3-10,12,15H,11,13-14H2,1-2H3,(H,30,35) QZMZZOCEJPCAIJ-UHFFFAOYSA-N 408668 N-[(2-fluoro-3-methoxyphenyl)methyl]-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide::US10364238, Example 4::US11001578, Example 4::US11084809, Example 4::US11198691, Example 4 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408668 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408668&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365107 406799302 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073008 COc1cccc(CNC(=O)c2cn(Cc3ccc(Cn4cc(C)cn4)cc3)nc2C(F)(F)F)c1 InChI=1S/C25H24F3N5O2/c1-17-11-30-32(13-17)14-18-6-8-19(9-7-18)15-33-16-22(23(31-33)25(26,27)28)24(34)29-12-20-4-3-5-21(10-20)35-2/h3-11,13,16H,12,14-15H2,1-2H3,(H,29,34) JLGLPBSVAUHGOI-UHFFFAOYSA-N 408671 N-[(3-methoxyphenyl)methyl]-1-({4-[(4-methylpyrazol-1-yl)methyl]phenyl}methyl)-3- (trifluoromethyl)pyrazole-4-carboxamide ::US10364238, Example 5::US11001578, Example 5::US11084809, Example 5::US11198691, Example 5 Plasma kallikrein Human 364 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408671 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408671&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365083 406799304 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073009 COc1cccc(CNC(=O)c2cn(Cc3ccc(Cn4cc(C)cn4)cc3)nc2C(F)(F)F)c1 InChI=1S/C25H24F3N5O2/c1-17-11-30-32(13-17)14-18-6-8-19(9-7-18)15-33-16-22(23(31-33)25(26,27)28)24(34)29-12-20-4-3-5-21(10-20)35-2/h3-11,13,16H,12,14-15H2,1-2H3,(H,29,34) JLGLPBSVAUHGOI-UHFFFAOYSA-N 408671 N-[(3-methoxyphenyl)methyl]-1-({4-[(4-methylpyrazol-1-yl)methyl]phenyl}methyl)-3- (trifluoromethyl)pyrazole-4-carboxamide ::US10364238, Example 5::US11001578, Example 5::US11084809, Example 5::US11198691, Example 5 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408671 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408671&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365083 406799304 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073010 CCOc1cccc(CNC(=O)c2cn(Cc3ccc(Cn4cc(C)cn4)cc3)nc2C(F)(F)F)c1 InChI=1S/C26H26F3N5O2/c1-3-36-22-6-4-5-21(11-22)13-30-25(35)23-17-34(32-24(23)26(27,28)29)16-20-9-7-19(8-10-20)15-33-14-18(2)12-31-33/h4-12,14,17H,3,13,15-16H2,1-2H3,(H,30,35) UJVJDICDWMSCMO-UHFFFAOYSA-N 408672 N-[(3-ethoxyphenyl)methyl]-1-({4-[(4-methylpyrazol-1-yl)methyl]phenyl}methyl)-3- (trifluoromethyl)pyrazole-4-carboxamide::US10364238, Example 6::US11001578, Example 6::US11084809, Example 6::US11198691, Example 6 Plasma kallikrein Human 2360 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408672 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408672&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365014 406799305 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073011 CCOc1cccc(CNC(=O)c2cn(Cc3ccc(Cn4cc(C)cn4)cc3)nc2C(F)(F)F)c1 InChI=1S/C26H26F3N5O2/c1-3-36-22-6-4-5-21(11-22)13-30-25(35)23-17-34(32-24(23)26(27,28)29)16-20-9-7-19(8-10-20)15-33-14-18(2)12-31-33/h4-12,14,17H,3,13,15-16H2,1-2H3,(H,30,35) UJVJDICDWMSCMO-UHFFFAOYSA-N 408672 N-[(3-ethoxyphenyl)methyl]-1-({4-[(4-methylpyrazol-1-yl)methyl]phenyl}methyl)-3- (trifluoromethyl)pyrazole-4-carboxamide::US10364238, Example 6::US11001578, Example 6::US11084809, Example 6::US11198691, Example 6 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408672 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408672&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365014 406799305 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073012 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4cccc(OC(F)(F)F)c4)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C25H21F6N5O2/c1-16-10-33-35(12-16)13-17-5-7-18(8-6-17)14-36-15-21(22(34-36)24(26,27)28)23(37)32-11-19-3-2-4-20(9-19)38-25(29,30)31/h2-10,12,15H,11,13-14H2,1H3,(H,32,37) IWQRRWVFCUYKBA-UHFFFAOYSA-N 408674 1-({4-[(4-methylpyrazol-1-yl)methyl]phenyl}methyl)-N-{[3- (trifluoromethoxy)phenyl]methyl}-3-(trifluoromethyl)pyrazole-4-carboxamide ::US10364238, Example 7::US11001578, Example 7::US11084809, Example 7::US11198691, Example 7 Plasma kallikrein Human >10000 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408674 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408674&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365116 406799307 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073013 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4cccc(OC(F)(F)F)c4)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C25H21F6N5O2/c1-16-10-33-35(12-16)13-17-5-7-18(8-6-17)14-36-15-21(22(34-36)24(26,27)28)23(37)32-11-19-3-2-4-20(9-19)38-25(29,30)31/h2-10,12,15H,11,13-14H2,1H3,(H,32,37) IWQRRWVFCUYKBA-UHFFFAOYSA-N 408674 1-({4-[(4-methylpyrazol-1-yl)methyl]phenyl}methyl)-N-{[3- (trifluoromethoxy)phenyl]methyl}-3-(trifluoromethyl)pyrazole-4-carboxamide ::US10364238, Example 7::US11001578, Example 7::US11084809, Example 7::US11198691, Example 7 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408674 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408674&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365116 406799307 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073014 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ccc(C)cc4)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C25H24F3N5O/c1-17-3-5-19(6-4-17)12-29-24(34)22-16-33(31-23(22)25(26,27)28)15-21-9-7-20(8-10-21)14-32-13-18(2)11-30-32/h3-11,13,16H,12,14-15H2,1-2H3,(H,29,34) UWKOAYQJMJZTCL-UHFFFAOYSA-N 497235 N-[(4-methylphenyl)methyl]-1-({4-[(4-methylpyrazol-1-yl)methyl]phenyl}methyl)-3-::US11001578, Example 8::US11084809, Example 8::US11198691, Example 8 Plasma kallikrein Human 539 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=497235 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=497235&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365038 459070223 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073015 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ccc(C)cc4)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C25H24F3N5O/c1-17-3-5-19(6-4-17)12-29-24(34)22-16-33(31-23(22)25(26,27)28)15-21-9-7-20(8-10-21)14-32-13-18(2)11-30-32/h3-11,13,16H,12,14-15H2,1-2H3,(H,29,34) UWKOAYQJMJZTCL-UHFFFAOYSA-N 497235 N-[(4-methylphenyl)methyl]-1-({4-[(4-methylpyrazol-1-yl)methyl]phenyl}methyl)-3-::US11001578, Example 8::US11084809, Example 8::US11198691, Example 8 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=497235 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=497235&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365038 459070223 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073016 COc1ccc(F)c(CNC(=O)c2cn(Cc3ccc(Cn4cc(C)cn4)cc3)nc2C(F)(F)F)c1 InChI=1S/C25H23F4N5O2/c1-16-10-31-33(12-16)13-17-3-5-18(6-4-17)14-34-15-21(23(32-34)25(27,28)29)24(35)30-11-19-9-20(36-2)7-8-22(19)26/h3-10,12,15H,11,13-14H2,1-2H3,(H,30,35) HQJUOFQTROTCAB-UHFFFAOYSA-N 408678 N-[(2-fluoro-5-methoxyphenyl)methyl]-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide ::US10364238, Example 9::US11001578, Example 9::US11084809, Example 9::US11198691, Example 9 Plasma kallikrein Human 239 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408678 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408678&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365002 406799311 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073017 COc1ccc(F)c(CNC(=O)c2cn(Cc3ccc(Cn4cc(C)cn4)cc3)nc2C(F)(F)F)c1 InChI=1S/C25H23F4N5O2/c1-16-10-31-33(12-16)13-17-3-5-18(6-4-17)14-34-15-21(23(32-34)25(27,28)29)24(35)30-11-19-9-20(36-2)7-8-22(19)26/h3-10,12,15H,11,13-14H2,1-2H3,(H,30,35) HQJUOFQTROTCAB-UHFFFAOYSA-N 408678 N-[(2-fluoro-5-methoxyphenyl)methyl]-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide ::US10364238, Example 9::US11001578, Example 9::US11084809, Example 9::US11198691, Example 9 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408678 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408678&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365002 406799311 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073018 COc1ccc(CNC(=O)c2cn(Cc3ccc(Cn4cc(C)cn4)cc3)nc2C(F)(F)F)c(OC)c1 InChI=1S/C26H26F3N5O3/c1-17-11-31-33(13-17)14-18-4-6-19(7-5-18)15-34-16-22(24(32-34)26(27,28)29)25(35)30-12-20-8-9-21(36-2)10-23(20)37-3/h4-11,13,16H,12,14-15H2,1-3H3,(H,30,35) CXDMHDUCUCLAEV-UHFFFAOYSA-N 408681 N-[(2,4-dimethoxyphenyl)methyl]-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide ::US10364238, Example 10::US11001578, Example 10::US11084809, Example 10::US11198691, Example 10 Plasma kallikrein Human 1270 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408681 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408681&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365034 406799314 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073019 COc1ccc(CNC(=O)c2cn(Cc3ccc(Cn4cc(C)cn4)cc3)nc2C(F)(F)F)c(OC)c1 InChI=1S/C26H26F3N5O3/c1-17-11-31-33(13-17)14-18-4-6-19(7-5-18)15-34-16-22(24(32-34)26(27,28)29)25(35)30-12-20-8-9-21(36-2)10-23(20)37-3/h4-11,13,16H,12,14-15H2,1-3H3,(H,30,35) CXDMHDUCUCLAEV-UHFFFAOYSA-N 408681 N-[(2,4-dimethoxyphenyl)methyl]-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide ::US10364238, Example 10::US11001578, Example 10::US11084809, Example 10::US11198691, Example 10 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408681 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408681&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365034 406799314 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073020 COc1cc(F)c(CNC(=O)c2cn(Cc3ccc(Cn4cc(C)cn4)cc3)nc2C(F)(F)F)c(F)c1 InChI=1S/C25H22F5N5O2/c1-15-9-32-34(11-15)12-16-3-5-17(6-4-16)13-35-14-20(23(33-35)25(28,29)30)24(36)31-10-19-21(26)7-18(37-2)8-22(19)27/h3-9,11,14H,10,12-13H2,1-2H3,(H,31,36) HRWXHWAUCMAPKJ-UHFFFAOYSA-N 408683 N-[(2,6-difluoro-4-methoxyphenyl)methyl]-1-({4-[(4-methylpyrazol-1- yl)methyl]pheny}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide::US10364238, Example 11::US11001578, Example 11::US11084809, Example 11::US11198691, Example 11 Plasma kallikrein Human 456 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408683 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408683&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365073 406799316 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073021 COc1cc(F)c(CNC(=O)c2cn(Cc3ccc(Cn4cc(C)cn4)cc3)nc2C(F)(F)F)c(F)c1 InChI=1S/C25H22F5N5O2/c1-15-9-32-34(11-15)12-16-3-5-17(6-4-16)13-35-14-20(23(33-35)25(28,29)30)24(36)31-10-19-21(26)7-18(37-2)8-22(19)27/h3-9,11,14H,10,12-13H2,1-2H3,(H,31,36) HRWXHWAUCMAPKJ-UHFFFAOYSA-N 408683 N-[(2,6-difluoro-4-methoxyphenyl)methyl]-1-({4-[(4-methylpyrazol-1- yl)methyl]pheny}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide::US10364238, Example 11::US11001578, Example 11::US11084809, Example 11::US11198691, Example 11 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408683 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408683&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365073 406799316 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073022 COc1ccc(CNC(=O)c2cn(Cc3ccc(Cn4cc(C)cn4)cc3)nc2C(F)(F)F)c(c1)C(F)(F)F InChI=1S/C26H23F6N5O2/c1-16-10-34-36(12-16)13-17-3-5-18(6-4-17)14-37-15-21(23(35-37)26(30,31)32)24(38)33-11-19-7-8-20(39-2)9-22(19)25(27,28)29/h3-10,12,15H,11,13-14H2,1-2H3,(H,33,38) UJRPEIINPALAES-UHFFFAOYSA-N 408685 N-{[4-methoxy-2-(trifluoromethyl)phenyl]methyl}-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide ::US10364238, Example 12::US11001578, Example 12::US11084809, Example 12::US11198691, Example 12 Plasma kallikrein Human 746 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408685 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408685&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365025 406799318 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073023 COc1ccc(CNC(=O)c2cn(Cc3ccc(Cn4cc(C)cn4)cc3)nc2C(F)(F)F)c(c1)C(F)(F)F InChI=1S/C26H23F6N5O2/c1-16-10-34-36(12-16)13-17-3-5-18(6-4-17)14-37-15-21(23(35-37)26(30,31)32)24(38)33-11-19-7-8-20(39-2)9-22(19)25(27,28)29/h3-10,12,15H,11,13-14H2,1-2H3,(H,33,38) UJRPEIINPALAES-UHFFFAOYSA-N 408685 N-{[4-methoxy-2-(trifluoromethyl)phenyl]methyl}-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide ::US10364238, Example 12::US11001578, Example 12::US11084809, Example 12::US11198691, Example 12 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408685 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408685&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365025 406799318 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073024 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4c(F)cccc4F)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C24H20F5N5O/c1-15-9-31-33(11-15)12-16-5-7-17(8-6-16)13-34-14-19(22(32-34)24(27,28)29)23(35)30-10-18-20(25)3-2-4-21(18)26/h2-9,11,14H,10,12-13H2,1H3,(H,30,35) DRFYBIDDXPOTJQ-UHFFFAOYSA-N 512283 N-[(2,6-difluorophenyl)methyl]-1-({4-[(4-methylpyrazol-1-yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide::US11084809, Example 13::US11198691, Example 13 Plasma kallikrein Human 439 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=512283 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=512283&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121364996 459629531 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073025 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4c(F)cccc4F)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C24H20F5N5O/c1-15-9-31-33(11-15)12-16-5-7-17(8-6-16)13-34-14-19(22(32-34)24(27,28)29)23(35)30-10-18-20(25)3-2-4-21(18)26/h2-9,11,14H,10,12-13H2,1H3,(H,30,35) DRFYBIDDXPOTJQ-UHFFFAOYSA-N 512283 N-[(2,6-difluorophenyl)methyl]-1-({4-[(4-methylpyrazol-1-yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide::US11084809, Example 13::US11198691, Example 13 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=512283 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=512283&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121364996 459629531 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073026 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4c(F)cccc4Cl)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C24H20ClF4N5O/c1-15-9-31-33(11-15)12-16-5-7-17(8-6-16)13-34-14-19(22(32-34)24(27,28)29)23(35)30-10-18-20(25)3-2-4-21(18)26/h2-9,11,14H,10,12-13H2,1H3,(H,30,35) UCUUHDDHAAXSSH-UHFFFAOYSA-N 408689 N-[(2-chloro-6-fluorophenyl)methyl]-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide ::US10364238, Example 14::US11001578, Example 14::US11084809, Example 14::US11198691, Example 14 Plasma kallikrein Human 514 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408689 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408689&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365058 406799322 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073027 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4c(F)cccc4Cl)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C24H20ClF4N5O/c1-15-9-31-33(11-15)12-16-5-7-17(8-6-16)13-34-14-19(22(32-34)24(27,28)29)23(35)30-10-18-20(25)3-2-4-21(18)26/h2-9,11,14H,10,12-13H2,1H3,(H,30,35) UCUUHDDHAAXSSH-UHFFFAOYSA-N 408689 N-[(2-chloro-6-fluorophenyl)methyl]-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide ::US10364238, Example 14::US11001578, Example 14::US11084809, Example 14::US11198691, Example 14 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408689 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408689&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365058 406799322 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073028 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4c(F)cccc4C(F)(F)F)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C25H20F7N5O/c1-15-9-34-36(11-15)12-16-5-7-17(8-6-16)13-37-14-19(22(35-37)25(30,31)32)23(38)33-10-18-20(24(27,28)29)3-2-4-21(18)26/h2-9,11,14H,10,12-13H2,1H3,(H,33,38) MRFKCVIKSCVIEK-UHFFFAOYSA-N 408691 N-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide::US10364238, Example 15::US11001578, Example 15::US11084809, Example 15::US11198691, Example 15 Plasma kallikrein Human 219 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408691 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408691&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365041 406799324 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073029 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4c(F)cccc4C(F)(F)F)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C25H20F7N5O/c1-15-9-34-36(11-15)12-16-5-7-17(8-6-16)13-37-14-19(22(35-37)25(30,31)32)23(38)33-10-18-20(24(27,28)29)3-2-4-21(18)26/h2-9,11,14H,10,12-13H2,1H3,(H,33,38) MRFKCVIKSCVIEK-UHFFFAOYSA-N 408691 N-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide::US10364238, Example 15::US11001578, Example 15::US11084809, Example 15::US11198691, Example 15 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408691 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408691&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365041 406799324 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073030 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4c(F)cc(Cl)cc4F)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C24H19ClF5N5O/c1-14-8-32-34(10-14)11-15-2-4-16(5-3-15)12-35-13-19(22(33-35)24(28,29)30)23(36)31-9-18-20(26)6-17(25)7-21(18)27/h2-8,10,13H,9,11-12H2,1H3,(H,31,36) SXIKFYGPUGSYOC-UHFFFAOYSA-N 408692 N-[(4-chloro-2,6-difluorophenyl)methyl]-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide ::US10364238, Example 16::US11001578, Example 16::US11084809, Example 16::US11198691, Example 16 Plasma kallikrein Human 263 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408692 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408692&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365003 406799325 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073031 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4c(F)cc(Cl)cc4F)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C24H19ClF5N5O/c1-14-8-32-34(10-14)11-15-2-4-16(5-3-15)12-35-13-19(22(33-35)24(28,29)30)23(36)31-9-18-20(26)6-17(25)7-21(18)27/h2-8,10,13H,9,11-12H2,1H3,(H,31,36) SXIKFYGPUGSYOC-UHFFFAOYSA-N 408692 N-[(4-chloro-2,6-difluorophenyl)methyl]-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide ::US10364238, Example 16::US11001578, Example 16::US11084809, Example 16::US11198691, Example 16 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408692 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408692&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365003 406799325 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073032 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ccc(Cl)cc4F)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C24H20ClF4N5O/c1-15-9-31-33(11-15)12-16-2-4-17(5-3-16)13-34-14-20(22(32-34)24(27,28)29)23(35)30-10-18-6-7-19(25)8-21(18)26/h2-9,11,14H,10,12-13H2,1H3,(H,30,35) MPXDOEQMYFYSIT-UHFFFAOYSA-N 408693 N-[(4-chloro-2-fluorophenyl)methyl]-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide ::US10364238, Example 17::US11001578, Example 17::US11084809, Example 17::US11198691, Example 17 Plasma kallikrein Human 865 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408693 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408693&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365130 406799326 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073033 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ccc(Cl)cc4F)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C24H20ClF4N5O/c1-15-9-31-33(11-15)12-16-2-4-17(5-3-16)13-34-14-20(22(32-34)24(27,28)29)23(35)30-10-18-6-7-19(25)8-21(18)26/h2-9,11,14H,10,12-13H2,1H3,(H,30,35) MPXDOEQMYFYSIT-UHFFFAOYSA-N 408693 N-[(4-chloro-2-fluorophenyl)methyl]-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide ::US10364238, Example 17::US11001578, Example 17::US11084809, Example 17::US11198691, Example 17 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408693 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408693&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365130 406799326 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073034 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4c(F)ccc(Cl)c4F)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C24H19ClF5N5O/c1-14-8-32-34(10-14)11-15-2-4-16(5-3-15)12-35-13-18(22(33-35)24(28,29)30)23(36)31-9-17-20(26)7-6-19(25)21(17)27/h2-8,10,13H,9,11-12H2,1H3,(H,31,36) HNSAKACOONQHKG-UHFFFAOYSA-N 408694 N-[(3-chloro-2,6-difluorophenyl)methyl]-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide::US10364238, Example 18::US11001578, Example 18::US11084809, Example 18::US11198691, Example 18 Plasma kallikrein Human 373 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408694 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408694&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365160 406799327 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073035 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4c(F)ccc(Cl)c4F)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C24H19ClF5N5O/c1-14-8-32-34(10-14)11-15-2-4-16(5-3-15)12-35-13-18(22(33-35)24(28,29)30)23(36)31-9-17-20(26)7-6-19(25)21(17)27/h2-8,10,13H,9,11-12H2,1H3,(H,31,36) HNSAKACOONQHKG-UHFFFAOYSA-N 408694 N-[(3-chloro-2,6-difluorophenyl)methyl]-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide::US10364238, Example 18::US11001578, Example 18::US11084809, Example 18::US11198691, Example 18 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408694 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408694&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365160 406799327 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073036 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4cccc(Cl)c4F)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C24H20ClF4N5O/c1-15-9-31-33(11-15)12-16-5-7-17(8-6-16)13-34-14-19(22(32-34)24(27,28)29)23(35)30-10-18-3-2-4-20(25)21(18)26/h2-9,11,14H,10,12-13H2,1H3,(H,30,35) RFRZBYFPHZMTPR-UHFFFAOYSA-N 408695 N-[(3-chloro-2-fluorophenyl)methyl]-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide::US10364238, Example 19::US11001578, Example 19::US11084809, Example 19::US11198691, Example 19 Plasma kallikrein Human 1130 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408695 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408695&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365137 406799328 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073037 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4cccc(Cl)c4F)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C24H20ClF4N5O/c1-15-9-31-33(11-15)12-16-5-7-17(8-6-16)13-34-14-19(22(32-34)24(27,28)29)23(35)30-10-18-3-2-4-20(25)21(18)26/h2-9,11,14H,10,12-13H2,1H3,(H,30,35) RFRZBYFPHZMTPR-UHFFFAOYSA-N 408695 N-[(3-chloro-2-fluorophenyl)methyl]-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide::US10364238, Example 19::US11001578, Example 19::US11084809, Example 19::US11198691, Example 19 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408695 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408695&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365137 406799328 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073038 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4cc(Cl)ccc4F)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C24H20ClF4N5O/c1-15-9-31-33(11-15)12-16-2-4-17(5-3-16)13-34-14-20(22(32-34)24(27,28)29)23(35)30-10-18-8-19(25)6-7-21(18)26/h2-9,11,14H,10,12-13H2,1H3,(H,30,35) VQSXMSNNAGMGCB-UHFFFAOYSA-N 408696 N-[(5-chloro-2-fluorophenyl)methyl]-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide ::US10364238, Example 20::US11001578, Example 20::US11084809, Example 20::US11198691, Example 20 Plasma kallikrein Human 740 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408696 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408696&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365077 406799329 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073039 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4cc(Cl)ccc4F)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C24H20ClF4N5O/c1-15-9-31-33(11-15)12-16-2-4-17(5-3-16)13-34-14-20(22(32-34)24(27,28)29)23(35)30-10-18-8-19(25)6-7-21(18)26/h2-9,11,14H,10,12-13H2,1H3,(H,30,35) VQSXMSNNAGMGCB-UHFFFAOYSA-N 408696 N-[(5-chloro-2-fluorophenyl)methyl]-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide ::US10364238, Example 20::US11001578, Example 20::US11084809, Example 20::US11198691, Example 20 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408696 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408696&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365077 406799329 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073040 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4c(F)c(Cl)ccc4C(F)(F)F)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C25H19ClF7N5O/c1-14-8-35-37(10-14)11-15-2-4-16(5-3-15)12-38-13-18(22(36-38)25(31,32)33)23(39)34-9-17-19(24(28,29)30)6-7-20(26)21(17)27/h2-8,10,13H,9,11-12H2,1H3,(H,34,39) KVPLENMFVKIMRG-UHFFFAOYSA-N 408697 N-{[3-chloro-2-fluoro-6-(trifluoromethyl)phenyl]methyl}-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide ::US10364238, Example 21::US11001578, Example 21::US11084809, Example 21::US11198691, Example 21 Plasma kallikrein Human 257 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408697 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408697&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365161 406799330 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073041 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4c(F)c(Cl)ccc4C(F)(F)F)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C25H19ClF7N5O/c1-14-8-35-37(10-14)11-15-2-4-16(5-3-15)12-38-13-18(22(36-38)25(31,32)33)23(39)34-9-17-19(24(28,29)30)6-7-20(26)21(17)27/h2-8,10,13H,9,11-12H2,1H3,(H,34,39) KVPLENMFVKIMRG-UHFFFAOYSA-N 408697 N-{[3-chloro-2-fluoro-6-(trifluoromethyl)phenyl]methyl}-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide ::US10364238, Example 21::US11001578, Example 21::US11084809, Example 21::US11198691, Example 21 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408697 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408697&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365161 406799330 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073042 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4c(Cl)cccc4Cl)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C24H20Cl2F3N5O/c1-15-9-31-33(11-15)12-16-5-7-17(8-6-16)13-34-14-19(22(32-34)24(27,28)29)23(35)30-10-18-20(25)3-2-4-21(18)26/h2-9,11,14H,10,12-13H2,1H3,(H,30,35) UNJUOXQQTNMQSH-UHFFFAOYSA-N 497249 N-[(2,6-dichlorophenyl)methyl]-1-({4-[(4-methylpyrazol-1-yl)methyl]phenyl}methyl)-::US11001578, Example 22::US11084809, Example 22::US11198691, Example 22 Plasma kallikrein Human 1350 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=497249 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=497249&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365089 459070236 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073043 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4c(Cl)cccc4Cl)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C24H20Cl2F3N5O/c1-15-9-31-33(11-15)12-16-5-7-17(8-6-16)13-34-14-19(22(32-34)24(27,28)29)23(35)30-10-18-20(25)3-2-4-21(18)26/h2-9,11,14H,10,12-13H2,1H3,(H,30,35) UNJUOXQQTNMQSH-UHFFFAOYSA-N 497249 N-[(2,6-dichlorophenyl)methyl]-1-({4-[(4-methylpyrazol-1-yl)methyl]phenyl}methyl)-::US11001578, Example 22::US11084809, Example 22::US11198691, Example 22 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=497249 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=497249&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365089 459070236 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073044 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4cc(Cl)ccc4C(F)(F)F)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C25H20ClF6N5O/c1-15-9-34-36(11-15)12-16-2-4-17(5-3-16)13-37-14-20(22(35-37)25(30,31)32)23(38)33-10-18-8-19(26)6-7-21(18)24(27,28)29/h2-9,11,14H,10,12-13H2,1H3,(H,33,38) JUBFFEWNQIXKCQ-UHFFFAOYSA-N 408699 N-{[5-chloro-2-(trifluoromethyl)phenyl]methyl}-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide ::US10364238, Example 23::US11001578, Example 23::US11084809, Example 23::US11198691, Example 23 Plasma kallikrein Human 1060 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408699 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408699&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365020 406799332 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073045 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4cc(Cl)ccc4C(F)(F)F)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C25H20ClF6N5O/c1-15-9-34-36(11-15)12-16-2-4-17(5-3-16)13-37-14-20(22(35-37)25(30,31)32)23(38)33-10-18-8-19(26)6-7-21(18)24(27,28)29/h2-9,11,14H,10,12-13H2,1H3,(H,33,38) JUBFFEWNQIXKCQ-UHFFFAOYSA-N 408699 N-{[5-chloro-2-(trifluoromethyl)phenyl]methyl}-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide ::US10364238, Example 23::US11001578, Example 23::US11084809, Example 23::US11198691, Example 23 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408699 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408699&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365020 406799332 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073046 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ccc(C)cc4C)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C26H26F3N5O/c1-17-4-9-22(19(3)10-17)12-30-25(35)23-16-34(32-24(23)26(27,28)29)15-21-7-5-20(6-8-21)14-33-13-18(2)11-31-33/h4-11,13,16H,12,14-15H2,1-3H3,(H,30,35) SJWYCGZDPHPMRJ-UHFFFAOYSA-N 497251 N-[(2,4-dimethylphenyl)methyl]-1-({4-[(4-methylpyrazol-1-yl)methyl]phenyl}methyl)-::US11001578, Example 24::US11084809, Example 24::US11198691, Example 24 Plasma kallikrein Human 717 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=497251 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=497251&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365032 459070238 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073047 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ccc(C)cc4C)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C26H26F3N5O/c1-17-4-9-22(19(3)10-17)12-30-25(35)23-16-34(32-24(23)26(27,28)29)15-21-7-5-20(6-8-21)14-33-13-18(2)11-31-33/h4-11,13,16H,12,14-15H2,1-3H3,(H,30,35) SJWYCGZDPHPMRJ-UHFFFAOYSA-N 497251 N-[(2,4-dimethylphenyl)methyl]-1-({4-[(4-methylpyrazol-1-yl)methyl]phenyl}methyl)-::US11001578, Example 24::US11084809, Example 24::US11198691, Example 24 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=497251 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=497251&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365032 459070238 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073048 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4c(C)cccc4C)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C26H26F3N5O/c1-17-11-31-33(13-17)14-20-7-9-21(10-8-20)15-34-16-23(24(32-34)26(27,28)29)25(35)30-12-22-18(2)5-4-6-19(22)3/h4-11,13,16H,12,14-15H2,1-3H3,(H,30,35) GIPNBFUDUIQKSS-UHFFFAOYSA-N 497252 N-[(2,6-dimethylphenyl)methyl]-1-({4-[(4-methylpyrazol-1-yl)methyl]phenyl}methyl)-::US11001578, Example 25::US11084809, Example 25::US11198691, Example 25 Plasma kallikrein Human 1840 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=497252 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=497252&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365052 459070239 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073049 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4c(C)cccc4C)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C26H26F3N5O/c1-17-11-31-33(13-17)14-20-7-9-21(10-8-20)15-34-16-23(24(32-34)26(27,28)29)25(35)30-12-22-18(2)5-4-6-19(22)3/h4-11,13,16H,12,14-15H2,1-3H3,(H,30,35) GIPNBFUDUIQKSS-UHFFFAOYSA-N 497252 N-[(2,6-dimethylphenyl)methyl]-1-({4-[(4-methylpyrazol-1-yl)methyl]phenyl}methyl)-::US11001578, Example 25::US11084809, Example 25::US11198691, Example 25 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=497252 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=497252&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365052 459070239 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073050 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4c(C)cc(C)cc4C)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C27H28F3N5O/c1-17-9-19(3)23(20(4)10-17)12-31-26(36)24-16-35(33-25(24)27(28,29)30)15-22-7-5-21(6-8-22)14-34-13-18(2)11-32-34/h5-11,13,16H,12,14-15H2,1-4H3,(H,31,36) YRBWCDOHOBNJLH-UHFFFAOYSA-N 408705 1-({4-[(4-methylpyrazol-1-yl)methyl]phenyl}methyl)-3-(trifluoromethyl)-N-[(2,4,6- trimethylphenyl)methyl]pyrazole-4-carboxamide::US10364238, Example 26::US11001578, Example 26::US11084809, Example 26::US11198691, Example 26 Plasma kallikrein Human 1340 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408705 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408705&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365037 406799338 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073051 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4c(C)cc(C)cc4C)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C27H28F3N5O/c1-17-9-19(3)23(20(4)10-17)12-31-26(36)24-16-35(33-25(24)27(28,29)30)15-22-7-5-21(6-8-22)14-34-13-18(2)11-32-34/h5-11,13,16H,12,14-15H2,1-4H3,(H,31,36) YRBWCDOHOBNJLH-UHFFFAOYSA-N 408705 1-({4-[(4-methylpyrazol-1-yl)methyl]phenyl}methyl)-3-(trifluoromethyl)-N-[(2,4,6- trimethylphenyl)methyl]pyrazole-4-carboxamide::US10364238, Example 26::US11001578, Example 26::US11084809, Example 26::US11198691, Example 26 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408705 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408705&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365037 406799338 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073052 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4cccc(F)c4C)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C25H23F4N5O/c1-16-10-31-33(12-16)13-18-6-8-19(9-7-18)14-34-15-21(23(32-34)25(27,28)29)24(35)30-11-20-4-3-5-22(26)17(20)2/h3-10,12,15H,11,13-14H2,1-2H3,(H,30,35) VMUDSUQWHSSZHZ-UHFFFAOYSA-N 408707 N-[(3-fluoro-2-methylphenyl)methyl]-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide ::US10364238, Example 27::US11001578, Example 27::US11084809, Example 27::US11198691, Example 27 Plasma kallikrein Human >10000 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408707 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408707&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365082 406799340 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073053 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4cccc(F)c4C)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C25H23F4N5O/c1-16-10-31-33(12-16)13-18-6-8-19(9-7-18)14-34-15-21(23(32-34)25(27,28)29)24(35)30-11-20-4-3-5-22(26)17(20)2/h3-10,12,15H,11,13-14H2,1-2H3,(H,30,35) VMUDSUQWHSSZHZ-UHFFFAOYSA-N 408707 N-[(3-fluoro-2-methylphenyl)methyl]-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide ::US10364238, Example 27::US11001578, Example 27::US11084809, Example 27::US11198691, Example 27 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408707 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408707&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365082 406799340 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073054 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ccc(C)cc4F)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C25H23F4N5O/c1-16-3-8-20(22(26)9-16)11-30-24(35)21-15-34(32-23(21)25(27,28)29)14-19-6-4-18(5-7-19)13-33-12-17(2)10-31-33/h3-10,12,15H,11,13-14H2,1-2H3,(H,30,35) OAWJOZMRPBQRIM-UHFFFAOYSA-N 408708 N-[(2-fluoro-4-methylphenyl)methyl]-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide ::US10364238, Example 28::US11001578, Example 28::US11084809, Example 28::US11198691, Example 28 Plasma kallikrein Human 280 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408708 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408708&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365048 406799341 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073055 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ccc(C)cc4F)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C25H23F4N5O/c1-16-3-8-20(22(26)9-16)11-30-24(35)21-15-34(32-23(21)25(27,28)29)14-19-6-4-18(5-7-19)13-33-12-17(2)10-31-33/h3-10,12,15H,11,13-14H2,1-2H3,(H,30,35) OAWJOZMRPBQRIM-UHFFFAOYSA-N 408708 N-[(2-fluoro-4-methylphenyl)methyl]-1-({4-[(4-methylpyrazol-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide ::US10364238, Example 28::US11001578, Example 28::US11084809, Example 28::US11198691, Example 28 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408708 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408708&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365048 406799341 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073056 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ncccc4F)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C23H20F4N6O/c1-15-9-30-32(11-15)12-16-4-6-17(7-5-16)13-33-14-18(21(31-33)23(25,26)27)22(34)29-10-20-19(24)3-2-8-28-20/h2-9,11,14H,10,12-13H2,1H3,(H,29,34) VBWIRJJMHLFZTC-UHFFFAOYSA-N 497256 N-[(3-fluoropyridin-2-yl)methyl]-1-({4-[(4-methylpyrazol-1-yl)methyl]phenyl}methyl)-::US11001578, Example 29::US11084809, Example 29::US11198691, Example 29 Plasma kallikrein Human 2190 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=497256 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=497256&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365018 459070243 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073057 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4ncccc4F)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C23H20F4N6O/c1-15-9-30-32(11-15)12-16-4-6-17(7-5-16)13-33-14-18(21(31-33)23(25,26)27)22(34)29-10-20-19(24)3-2-8-28-20/h2-9,11,14H,10,12-13H2,1H3,(H,29,34) VBWIRJJMHLFZTC-UHFFFAOYSA-N 497256 N-[(3-fluoropyridin-2-yl)methyl]-1-({4-[(4-methylpyrazol-1-yl)methyl]phenyl}methyl)-::US11001578, Example 29::US11084809, Example 29::US11198691, Example 29 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=497256 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=497256&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365018 459070243 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073058 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4cc(Cl)ccn4)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C23H20ClF3N6O/c1-15-9-30-32(11-15)12-16-2-4-17(5-3-16)13-33-14-20(21(31-33)23(25,26)27)22(34)29-10-19-8-18(24)6-7-28-19/h2-9,11,14H,10,12-13H2,1H3,(H,29,34) QSGBIRDROIJUJZ-UHFFFAOYSA-N 497257 N-[(4-chloropyridin-2-yl)methyl]-1-({4-[(4-methylpyrazol-1-yl)methyl]phenyl}methyl)-::US11001578, Example 30::US11084809, Example 30::US11198691, Example 30 Plasma kallikrein Human 915 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=497257 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=497257&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365099 459070244 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073059 Cc1cnn(Cc2ccc(Cn3cc(C(=O)NCc4cc(Cl)ccn4)c(n3)C(F)(F)F)cc2)c1 InChI=1S/C23H20ClF3N6O/c1-15-9-30-32(11-15)12-16-2-4-17(5-3-16)13-33-14-20(21(31-33)23(25,26)27)22(34)29-10-19-8-18(24)6-7-28-19/h2-9,11,14H,10,12-13H2,1H3,(H,29,34) QSGBIRDROIJUJZ-UHFFFAOYSA-N 497257 N-[(4-chloropyridin-2-yl)methyl]-1-({4-[(4-methylpyrazol-1-yl)methyl]phenyl}methyl)-::US11001578, Example 30::US11084809, Example 30::US11198691, Example 30 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=497257 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=497257&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365099 459070244 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073060 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cnccc1C(F)(F)F InChI=1S/C26H24F3N5O3/c1-37-17-23-21(25(36)31-13-20-12-30-10-9-22(20)26(27,28)29)16-34(32-23)15-19-7-5-18(6-8-19)14-33-11-3-2-4-24(33)35/h2-12,16H,13-15,17H2,1H3,(H,31,36) ZHJJZIGZXRDDHP-UHFFFAOYSA-N 408711 3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)-N-{[4- (trifluoromethyl)pyridin-3-yl]methyl}pyrazole-4-carboxamide ::US10364238, Example 31::US10364238, Example 37::US11001578, Example 37::US11084809, Example 37::US11198691, Example 37 Plasma kallikrein Human 392 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408711 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408711&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365063 406799344 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073061 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cnccc1C(F)(F)F InChI=1S/C26H24F3N5O3/c1-37-17-23-21(25(36)31-13-20-12-30-10-9-22(20)26(27,28)29)16-34(32-23)15-19-7-5-18(6-8-19)14-33-11-3-2-4-24(33)35/h2-12,16H,13-15,17H2,1H3,(H,31,36) ZHJJZIGZXRDDHP-UHFFFAOYSA-N 408711 3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)-N-{[4- (trifluoromethyl)pyridin-3-yl]methyl}pyrazole-4-carboxamide ::US10364238, Example 31::US10364238, Example 37::US11001578, Example 37::US11084809, Example 37::US11198691, Example 37 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408711 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408711&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365063 406799344 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073062 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1ccc(C)nc1 InChI=1S/C26H27N5O3/c1-19-6-7-22(13-27-19)14-28-26(33)23-17-31(29-24(23)18-34-2)16-21-10-8-20(9-11-21)15-30-12-4-3-5-25(30)32/h3-13,17H,14-16,18H2,1-2H3,(H,28,33) IKFHJYIVYYFDCA-UHFFFAOYSA-N 408712 3-(methoxymethyl)-N-[(6-methylpyridin-3-yl)methyl]-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 32::US10364238, Example 39::US11001578, Example 39::US11084809, Example 39::US11198691, Example 39 Plasma kallikrein Human 7870 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408712 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408712&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365092 406799345 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073063 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1ccc(C)nc1 InChI=1S/C26H27N5O3/c1-19-6-7-22(13-27-19)14-28-26(33)23-17-31(29-24(23)18-34-2)16-21-10-8-20(9-11-21)15-30-12-4-3-5-25(30)32/h3-13,17H,14-16,18H2,1-2H3,(H,28,33) IKFHJYIVYYFDCA-UHFFFAOYSA-N 408712 3-(methoxymethyl)-N-[(6-methylpyridin-3-yl)methyl]-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 32::US10364238, Example 39::US11001578, Example 39::US11084809, Example 39::US11198691, Example 39 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408712 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408712&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365092 406799345 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073064 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cccnc1C(F)(F)F InChI=1S/C26H24F3N5O3/c1-37-17-22-21(25(36)31-13-20-5-4-11-30-24(20)26(27,28)29)16-34(32-22)15-19-9-7-18(8-10-19)14-33-12-3-2-6-23(33)35/h2-12,16H,13-15,17H2,1H3,(H,31,36) ULAOQOFMZICMAA-UHFFFAOYSA-N 408713 3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)-N-{[2- (trifluoromethyl)pyridin-3-yl]methyl}pyrazole-4-carboxamide::US10364238, Example 36::US11001578, Example 36::US11084809, Example 36::US11198691, Example 36 Plasma kallikrein Human 4170 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408713 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408713&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365101 406799346 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073065 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cccnc1C(F)(F)F InChI=1S/C26H24F3N5O3/c1-37-17-22-21(25(36)31-13-20-5-4-11-30-24(20)26(27,28)29)16-34(32-22)15-19-9-7-18(8-10-19)14-33-12-3-2-6-23(33)35/h2-12,16H,13-15,17H2,1H3,(H,31,36) ULAOQOFMZICMAA-UHFFFAOYSA-N 408713 3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)-N-{[2- (trifluoromethyl)pyridin-3-yl]methyl}pyrazole-4-carboxamide::US10364238, Example 36::US11001578, Example 36::US11084809, Example 36::US11198691, Example 36 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408713 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408713&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365101 406799346 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073066 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cnccc1C(F)(F)F InChI=1S/C26H24F3N5O3/c1-37-17-23-21(25(36)31-13-20-12-30-10-9-22(20)26(27,28)29)16-34(32-23)15-19-7-5-18(6-8-19)14-33-11-3-2-4-24(33)35/h2-12,16H,13-15,17H2,1H3,(H,31,36) ZHJJZIGZXRDDHP-UHFFFAOYSA-N 408711 3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)-N-{[4- (trifluoromethyl)pyridin-3-yl]methyl}pyrazole-4-carboxamide ::US10364238, Example 31::US10364238, Example 37::US11001578, Example 37::US11084809, Example 37::US11198691, Example 37 Plasma kallikrein Human 392 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408711 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408711&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365063 406799344 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073067 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cnccc1C(F)(F)F InChI=1S/C26H24F3N5O3/c1-37-17-23-21(25(36)31-13-20-12-30-10-9-22(20)26(27,28)29)16-34(32-23)15-19-7-5-18(6-8-19)14-33-11-3-2-4-24(33)35/h2-12,16H,13-15,17H2,1H3,(H,31,36) ZHJJZIGZXRDDHP-UHFFFAOYSA-N 408711 3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)-N-{[4- (trifluoromethyl)pyridin-3-yl]methyl}pyrazole-4-carboxamide ::US10364238, Example 31::US10364238, Example 37::US11001578, Example 37::US11084809, Example 37::US11198691, Example 37 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408711 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408711&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365063 406799344 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073068 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1ccc(C)nc1 InChI=1S/C26H27N5O3/c1-19-6-7-22(13-27-19)14-28-26(33)23-17-31(29-24(23)18-34-2)16-21-10-8-20(9-11-21)15-30-12-4-3-5-25(30)32/h3-13,17H,14-16,18H2,1-2H3,(H,28,33) IKFHJYIVYYFDCA-UHFFFAOYSA-N 408712 3-(methoxymethyl)-N-[(6-methylpyridin-3-yl)methyl]-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 32::US10364238, Example 39::US11001578, Example 39::US11084809, Example 39::US11198691, Example 39 Plasma kallikrein Human 7870 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408712 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408712&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365092 406799345 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073069 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1ccc(C)nc1 InChI=1S/C26H27N5O3/c1-19-6-7-22(13-27-19)14-28-26(33)23-17-31(29-24(23)18-34-2)16-21-10-8-20(9-11-21)15-30-12-4-3-5-25(30)32/h3-13,17H,14-16,18H2,1-2H3,(H,28,33) IKFHJYIVYYFDCA-UHFFFAOYSA-N 408712 3-(methoxymethyl)-N-[(6-methylpyridin-3-yl)methyl]-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 32::US10364238, Example 39::US11001578, Example 39::US11084809, Example 39::US11198691, Example 39 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408712 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408712&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365092 406799345 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073070 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cccc(OC)n1 InChI=1S/C26H27N5O4/c1-34-18-23-22(26(33)27-14-21-6-5-7-24(28-21)35-2)17-31(29-23)16-20-11-9-19(10-12-20)15-30-13-4-3-8-25(30)32/h3-13,17H,14-16,18H2,1-2H3,(H,27,33) XOCSKLGONWNPHT-UHFFFAOYSA-N 408716 3-(methoxymethyl)-N-[(6-methoxypyridin-2-yl)methyl]-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 40::US11001578, Example 40::US11084809, Example 40::US11198691, Example 40 Plasma kallikrein Human 3700 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408716 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408716&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365155 406799347 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073071 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cccc(OC)n1 InChI=1S/C26H27N5O4/c1-34-18-23-22(26(33)27-14-21-6-5-7-24(28-21)35-2)17-31(29-23)16-20-11-9-19(10-12-20)15-30-13-4-3-8-25(30)32/h3-13,17H,14-16,18H2,1-2H3,(H,27,33) XOCSKLGONWNPHT-UHFFFAOYSA-N 408716 3-(methoxymethyl)-N-[(6-methoxypyridin-2-yl)methyl]-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 40::US11001578, Example 40::US11084809, Example 40::US11198691, Example 40 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408716 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408716&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365155 406799347 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073072 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1nccc(OC)c1F InChI=1S/C26H26FN5O4/c1-35-17-22-20(26(34)29-13-21-25(27)23(36-2)10-11-28-21)16-32(30-22)15-19-8-6-18(7-9-19)14-31-12-4-3-5-24(31)33/h3-12,16H,13-15,17H2,1-2H3,(H,29,34) KGMPDQIYDKKXRD-UHFFFAOYSA-N 408717 N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin- 1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 41::US10730874, Example 00397::US11001578, Example 41::US11084809, Example 41::US11198691, Example 41::US11352356, Table II.3::US11584735, Example 41 of WO2016/083820 Plasma kallikrein Human 3.30 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408717 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408717&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365142 406799348 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073073 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1nccc(OC)c1F InChI=1S/C26H26FN5O4/c1-35-17-22-20(26(34)29-13-21-25(27)23(36-2)10-11-28-21)16-32(30-22)15-19-8-6-18(7-9-19)14-31-12-4-3-5-24(31)33/h3-12,16H,13-15,17H2,1-2H3,(H,29,34) KGMPDQIYDKKXRD-UHFFFAOYSA-N 408717 N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin- 1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 41::US10730874, Example 00397::US11001578, Example 41::US11084809, Example 41::US11198691, Example 41::US11352356, Table II.3::US11584735, Example 41 of WO2016/083820 Kallikrein-1 Human >40000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408717 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408717&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365142 406799348 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073074 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1nc(OC)ccc1F InChI=1S/C26H26FN5O4/c1-35-17-23-20(26(34)28-13-22-21(27)10-11-24(29-22)36-2)16-32(30-23)15-19-8-6-18(7-9-19)14-31-12-4-3-5-25(31)33/h3-12,16H,13-15,17H2,1-2H3,(H,28,34) KQSCQCAZZHSOOR-UHFFFAOYSA-N 408718 N-[(3-fluoro-6-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin- 1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 42::US11001578, Example 42::US11084809, Example 42::US11198691, Example 42 Plasma kallikrein Human 831 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408718 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408718&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365159 406799349 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073075 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1nc(OC)ccc1F InChI=1S/C26H26FN5O4/c1-35-17-23-20(26(34)28-13-22-21(27)10-11-24(29-22)36-2)16-32(30-23)15-19-8-6-18(7-9-19)14-31-12-4-3-5-25(31)33/h3-12,16H,13-15,17H2,1-2H3,(H,28,34) KQSCQCAZZHSOOR-UHFFFAOYSA-N 408718 N-[(3-fluoro-6-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin- 1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 42::US11001578, Example 42::US11084809, Example 42::US11198691, Example 42 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408718 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408718&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365159 406799349 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073076 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1csc2ccc(Cl)cc12 InChI=1S/C28H25ClN4O3S/c1-36-17-25-24(28(35)30-13-21-18-37-26-10-9-22(29)12-23(21)26)16-33(31-25)15-20-7-5-19(6-8-20)14-32-11-3-2-4-27(32)34/h2-12,16,18H,13-15,17H2,1H3,(H,30,35) TZULTWISCDFBIR-UHFFFAOYSA-N 408719 N-[(5-chloro-1-benzothiophen-3-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin- 1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 45::US11001578, Example 45::US11084809, Example 45::US11198691, Example 45 Plasma kallikrein Human 144 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408719 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408719&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365070 406799350 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073077 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1csc2ccc(Cl)cc12 InChI=1S/C28H25ClN4O3S/c1-36-17-25-24(28(35)30-13-21-18-37-26-10-9-22(29)12-23(21)26)16-33(31-25)15-20-7-5-19(6-8-20)14-32-11-3-2-4-27(32)34/h2-12,16,18H,13-15,17H2,1H3,(H,30,35) TZULTWISCDFBIR-UHFFFAOYSA-N 408719 N-[(5-chloro-1-benzothiophen-3-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin- 1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 45::US11001578, Example 45::US11084809, Example 45::US11198691, Example 45 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408719 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408719&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365070 406799350 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073078 COCc1nn(Cc2ccc(nc2)N2CCCC2)cc1C(=O)NCc1csc2ccc(Cl)cc12 InChI=1S/C25H26ClN5O2S/c1-33-15-22-21(25(32)28-12-18-16-34-23-6-5-19(26)10-20(18)23)14-31(29-22)13-17-4-7-24(27-11-17)30-8-2-3-9-30/h4-7,10-11,14,16H,2-3,8-9,12-13,15H2,1H3,(H,28,32) WMNGADNOQNFZIE-UHFFFAOYSA-N 408720 N-[(5-chloro-1-benzothiophen-3-yl)methyl]-3-(methoxymethyl)-1-{[6-(pyrrolidin-1-::US10364238, Example 46::US11001578, Example 46::US11084809, Example 46::US11198691, Example 46 Plasma kallikrein Human 2400 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408720 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408720&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365148 406799351 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073079 COCc1nn(Cc2ccc(nc2)N2CCCC2)cc1C(=O)NCc1csc2ccc(Cl)cc12 InChI=1S/C25H26ClN5O2S/c1-33-15-22-21(25(32)28-12-18-16-34-23-6-5-19(26)10-20(18)23)14-31(29-22)13-17-4-7-24(27-11-17)30-8-2-3-9-30/h4-7,10-11,14,16H,2-3,8-9,12-13,15H2,1H3,(H,28,32) WMNGADNOQNFZIE-UHFFFAOYSA-N 408720 N-[(5-chloro-1-benzothiophen-3-yl)methyl]-3-(methoxymethyl)-1-{[6-(pyrrolidin-1-::US10364238, Example 46::US11001578, Example 46::US11084809, Example 46::US11198691, Example 46 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408720 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408720&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365148 406799351 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073080 COCc1nn(Cc2ccc(Cn3cc(C)cn3)cc2)cc1C(=O)NCc1csc2ccc(Cl)cc12 InChI=1S/C27H26ClN5O2S/c1-18-10-30-32(12-18)13-19-3-5-20(6-4-19)14-33-15-24(25(31-33)16-35-2)27(34)29-11-21-17-36-26-8-7-22(28)9-23(21)26/h3-10,12,15,17H,11,13-14,16H2,1-2H3,(H,29,34) OVCXPEFSYYWEMX-UHFFFAOYSA-N 408725 N-[(5-chloro-1-benzothiophen-3-yl)methyl]-3-(methoxymethyl)-1-({4-[(4- methylpyrazol-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 47::US11001578, Example 47::US11084809, Example 47::US11198691, Example 47 Plasma kallikrein Human 753 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408725 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408725&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365059 406799356 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073081 COCc1nn(Cc2ccc(Cn3cc(C)cn3)cc2)cc1C(=O)NCc1csc2ccc(Cl)cc12 InChI=1S/C27H26ClN5O2S/c1-18-10-30-32(12-18)13-19-3-5-20(6-4-19)14-33-15-24(25(31-33)16-35-2)27(34)29-11-21-17-36-26-8-7-22(28)9-23(21)26/h3-10,12,15,17H,11,13-14,16H2,1-2H3,(H,29,34) OVCXPEFSYYWEMX-UHFFFAOYSA-N 408725 N-[(5-chloro-1-benzothiophen-3-yl)methyl]-3-(methoxymethyl)-1-({4-[(4- methylpyrazol-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 47::US11001578, Example 47::US11084809, Example 47::US11198691, Example 47 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408725 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408725&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365059 406799356 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073082 NC(=O)c1ccccc1CNC(=O)c1cn(Cc2ccc(Cn3ccccc3=O)cc2)nc1C1CC1 InChI=1S/C28H27N5O3/c29-27(35)23-6-2-1-5-22(23)15-30-28(36)24-18-33(31-26(24)21-12-13-21)17-20-10-8-19(9-11-20)16-32-14-4-3-7-25(32)34/h1-11,14,18,21H,12-13,15-17H2,(H2,29,35)(H,30,36) KOYPCAXNSUCYIL-UHFFFAOYSA-N 408726 N-[(2-carbamoylphenyl)methyl]-3-cyclopropyl-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 48::US11001578, Example 48::US11084809, Example 48::US11198691, Example 48 Plasma kallikrein Human 647 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408726 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408726&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365021 406799357 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073083 NC(=O)c1ccccc1CNC(=O)c1cn(Cc2ccc(Cn3ccccc3=O)cc2)nc1C1CC1 InChI=1S/C28H27N5O3/c29-27(35)23-6-2-1-5-22(23)15-30-28(36)24-18-33(31-26(24)21-12-13-21)17-20-10-8-19(9-11-20)16-32-14-4-3-7-25(32)34/h1-11,14,18,21H,12-13,15-17H2,(H2,29,35)(H,30,36) KOYPCAXNSUCYIL-UHFFFAOYSA-N 408726 N-[(2-carbamoylphenyl)methyl]-3-cyclopropyl-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 48::US11001578, Example 48::US11084809, Example 48::US11198691, Example 48 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408726 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408726&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365021 406799357 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073084 NC(=O)c1cccc(CNC(=O)c2cn(Cc3ccc(Cn4ccccc4=O)cc3)nc2C2CC2)c1 InChI=1S/C28H27N5O3/c29-27(35)23-5-3-4-21(14-23)15-30-28(36)24-18-33(31-26(24)22-11-12-22)17-20-9-7-19(8-10-20)16-32-13-2-1-6-25(32)34/h1-10,13-14,18,22H,11-12,15-17H2,(H2,29,35)(H,30,36) GLBUGHLBAAXCAZ-UHFFFAOYSA-N 408727 N-[(3-carbamoylphenyl)methyl]-3-cyclopropyl-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 49::US11001578, Example 49::US11084809, Example 49::US11198691, Example 49 Plasma kallikrein Human 5450 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408727 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408727&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365022 406799358 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073085 NC(=O)c1cccc(CNC(=O)c2cn(Cc3ccc(Cn4ccccc4=O)cc3)nc2C2CC2)c1 InChI=1S/C28H27N5O3/c29-27(35)23-5-3-4-21(14-23)15-30-28(36)24-18-33(31-26(24)22-11-12-22)17-20-9-7-19(8-10-20)16-32-13-2-1-6-25(32)34/h1-10,13-14,18,22H,11-12,15-17H2,(H2,29,35)(H,30,36) GLBUGHLBAAXCAZ-UHFFFAOYSA-N 408727 N-[(3-carbamoylphenyl)methyl]-3-cyclopropyl-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 49::US11001578, Example 49::US11084809, Example 49::US11198691, Example 49 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408727 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408727&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365022 406799358 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073086 NC(=O)c1ccc(CNC(=O)c2cn(Cc3ccc(Cn4ccccc4=O)cc3)nc2C2CC2)cc1 InChI=1S/C28H27N5O3/c29-27(35)23-10-8-19(9-11-23)15-30-28(36)24-18-33(31-26(24)22-12-13-22)17-21-6-4-20(5-7-21)16-32-14-2-1-3-25(32)34/h1-11,14,18,22H,12-13,15-17H2,(H2,29,35)(H,30,36) XDXGOIDNTUZASE-UHFFFAOYSA-N 408730 N-[(4-carbamoylphenyl)methyl]-3-cyclopropyl-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 50::US11001578, Example 50::US11084809, Example 50::US11198691, Example 50 Plasma kallikrein Human 1800 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408730 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408730&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365075 406799361 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073087 NC(=O)c1ccc(CNC(=O)c2cn(Cc3ccc(Cn4ccccc4=O)cc3)nc2C2CC2)cc1 InChI=1S/C28H27N5O3/c29-27(35)23-10-8-19(9-11-23)15-30-28(36)24-18-33(31-26(24)22-12-13-22)17-21-6-4-20(5-7-21)16-32-14-2-1-3-25(32)34/h1-11,14,18,22H,12-13,15-17H2,(H2,29,35)(H,30,36) XDXGOIDNTUZASE-UHFFFAOYSA-N 408730 N-[(4-carbamoylphenyl)methyl]-3-cyclopropyl-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 50::US11001578, Example 50::US11084809, Example 50::US11198691, Example 50 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408730 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408730&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365075 406799361 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073088 Fc1cccc(c1CNC(=O)c1cn(Cc2ccc(Cn3ccccc3=O)cc2)nc1C(F)(F)F)C(F)(F)F InChI=1S/C26H19F7N4O2/c27-21-5-3-4-20(25(28,29)30)18(21)12-34-24(39)19-15-37(35-23(19)26(31,32)33)14-17-9-7-16(8-10-17)13-36-11-2-1-6-22(36)38/h1-11,15H,12-14H2,(H,34,39) ASCUMAURKSBUPS-UHFFFAOYSA-N 408732 N-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide::US10364238, Example 51::US11001578, Example 51::US11084809, Example 51::US11198691, Example 51 Plasma kallikrein Human 48.9 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408732 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408732&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365085 406799363 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073089 Fc1cccc(c1CNC(=O)c1cn(Cc2ccc(Cn3ccccc3=O)cc2)nc1C(F)(F)F)C(F)(F)F InChI=1S/C26H19F7N4O2/c27-21-5-3-4-20(25(28,29)30)18(21)12-34-24(39)19-15-37(35-23(19)26(31,32)33)14-17-9-7-16(8-10-17)13-36-11-2-1-6-22(36)38/h1-11,15H,12-14H2,(H,34,39) ASCUMAURKSBUPS-UHFFFAOYSA-N 408732 N-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide::US10364238, Example 51::US11001578, Example 51::US11084809, Example 51::US11198691, Example 51 Kallikrein-1 Human >40000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408732 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408732&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365085 406799363 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073090 COc1cccc(CNC(=O)c2cn(Cc3ccc(Cn4ccccc4=O)cc3)nc2C2CC2)c1F InChI=1S/C28H27FN4O3/c1-36-24-6-4-5-22(26(24)29)15-30-28(35)23-18-33(31-27(23)21-12-13-21)17-20-10-8-19(9-11-20)16-32-14-3-2-7-25(32)34/h2-11,14,18,21H,12-13,15-17H2,1H3,(H,30,35) NFLOZDGNLCLQAJ-UHFFFAOYSA-N 408733 3-cyclopropyl-N-[(2-fluoro-3-methoxyphenyl)methyl]-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 52::US11001578, Example 52::US11084809, Example 52::US11198691, Example 52 Plasma kallikrein Human 23.3 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408733 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408733&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365123 406799364 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073091 COc1cccc(CNC(=O)c2cn(Cc3ccc(Cn4ccccc4=O)cc3)nc2C2CC2)c1F InChI=1S/C28H27FN4O3/c1-36-24-6-4-5-22(26(24)29)15-30-28(35)23-18-33(31-27(23)21-12-13-21)17-20-10-8-19(9-11-20)16-32-14-3-2-7-25(32)34/h2-11,14,18,21H,12-13,15-17H2,1H3,(H,30,35) NFLOZDGNLCLQAJ-UHFFFAOYSA-N 408733 3-cyclopropyl-N-[(2-fluoro-3-methoxyphenyl)methyl]-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 52::US11001578, Example 52::US11084809, Example 52::US11198691, Example 52 Kallikrein-1 Human >40000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408733 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408733&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365123 406799364 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073092 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cccc(OC)c1F InChI=1S/C27H27FN4O4/c1-35-18-23-22(27(34)29-14-21-6-5-7-24(36-2)26(21)28)17-32(30-23)16-20-11-9-19(10-12-20)15-31-13-4-3-8-25(31)33/h3-13,17H,14-16,18H2,1-2H3,(H,29,34) MLCDWARNPOODOL-UHFFFAOYSA-N 408734 N-[(2-fluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide::US10364238, Example 53::US11001578, Example 53::US11084809, Example 53::US11198691, Example 53 Plasma kallikrein Human 20.2 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408734 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408734&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365056 406799365 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073093 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cccc(OC)c1F InChI=1S/C27H27FN4O4/c1-35-18-23-22(27(34)29-14-21-6-5-7-24(36-2)26(21)28)17-32(30-23)16-20-11-9-19(10-12-20)15-31-13-4-3-8-25(31)33/h3-13,17H,14-16,18H2,1-2H3,(H,29,34) MLCDWARNPOODOL-UHFFFAOYSA-N 408734 N-[(2-fluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide::US10364238, Example 53::US11001578, Example 53::US11084809, Example 53::US11198691, Example 53 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408734 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408734&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365056 406799365 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073094 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1c(OC)ccc(OC)c1F InChI=1S/C28H29FN4O5/c1-36-18-23-22(28(35)30-14-21-24(37-2)11-12-25(38-3)27(21)29)17-33(31-23)16-20-9-7-19(8-10-20)15-32-13-5-4-6-26(32)34/h4-13,17H,14-16,18H2,1-3H3,(H,30,35) TVHOOPXMFWZGQK-UHFFFAOYSA-N 408736 N-[(2-fluoro-3,6-dimethoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin- 1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 54::US11001578, Example 54::US11084809, Example 54::US11198691, Example 54 Plasma kallikrein Human 2.10 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408736 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408736&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365119 406799367 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073095 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1c(OC)ccc(OC)c1F InChI=1S/C28H29FN4O5/c1-36-18-23-22(28(35)30-14-21-24(37-2)11-12-25(38-3)27(21)29)17-33(31-23)16-20-9-7-19(8-10-20)15-32-13-5-4-6-26(32)34/h4-13,17H,14-16,18H2,1-3H3,(H,30,35) TVHOOPXMFWZGQK-UHFFFAOYSA-N 408736 N-[(2-fluoro-3,6-dimethoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin- 1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 54::US11001578, Example 54::US11084809, Example 54::US11198691, Example 54 Kallikrein-1 Human >40000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408736 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408736&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365119 406799367 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073096 Nc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1ccc(OC(F)(F)F)cc1 InChI=1S/C25H22F3N5O3/c26-25(27,28)36-20-10-8-17(9-11-20)13-30-24(35)21-16-33(31-23(21)29)15-19-6-4-18(5-7-19)14-32-12-2-1-3-22(32)34/h1-12,16H,13-15H2,(H2,29,31)(H,30,35) KRHKQKBRWFYZPN-UHFFFAOYSA-N 408737 3-amino-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)-N-{[4- (trifluoromethoxy)phenyl]methyl}pyrazole-4-carboxamide ::US10364238, Example 58::US11001578, Example 58::US11084809, Example 58::US11198691, Example 58 Plasma kallikrein Human 5780 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408737 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408737&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365068 406799368 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073097 Nc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1ccc(OC(F)(F)F)cc1 InChI=1S/C25H22F3N5O3/c26-25(27,28)36-20-10-8-17(9-11-20)13-30-24(35)21-16-33(31-23(21)29)15-19-6-4-18(5-7-19)14-32-12-2-1-3-22(32)34/h1-12,16H,13-15H2,(H2,29,31)(H,30,35) KRHKQKBRWFYZPN-UHFFFAOYSA-N 408737 3-amino-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)-N-{[4- (trifluoromethoxy)phenyl]methyl}pyrazole-4-carboxamide ::US10364238, Example 58::US11001578, Example 58::US11084809, Example 58::US11198691, Example 58 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408737 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408737&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365068 406799368 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073098 COc1cccc(CNC(=O)c2cn(Cc3ccc(Cn4ccccc4=O)cc3)nc2N(C)C)c1F InChI=1S/C27H28FN5O3/c1-31(2)26-22(27(35)29-15-21-7-6-8-23(36-3)25(21)28)18-33(30-26)17-20-12-10-19(11-13-20)16-32-14-5-4-9-24(32)34/h4-14,18H,15-17H2,1-3H3,(H,29,35) OMUPFLKDHHROJU-UHFFFAOYSA-N 408738 3-(dimethylamino)-N-[(2-fluoro-3-methoxyphenyl)methyl]-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 59::US11001578, Example 59::US11084809, Example 59::US11198691, Example 59 Plasma kallikrein Human 73.4 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408738 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408738&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365158 406799369 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073099 COc1cccc(CNC(=O)c2cn(Cc3ccc(Cn4ccccc4=O)cc3)nc2N(C)C)c1F InChI=1S/C27H28FN5O3/c1-31(2)26-22(27(35)29-15-21-7-6-8-23(36-3)25(21)28)18-33(30-26)17-20-12-10-19(11-13-20)16-32-14-5-4-9-24(32)34/h4-14,18H,15-17H2,1-3H3,(H,29,35) OMUPFLKDHHROJU-UHFFFAOYSA-N 408738 3-(dimethylamino)-N-[(2-fluoro-3-methoxyphenyl)methyl]-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 59::US11001578, Example 59::US11084809, Example 59::US11198691, Example 59 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408738 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408738&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365158 406799369 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073100 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1ccccc1F InChI=1S/C26H25FN4O3/c1-34-18-24-22(26(33)28-14-21-6-2-3-7-23(21)27)17-31(29-24)16-20-11-9-19(10-12-20)15-30-13-5-4-8-25(30)32/h2-13,17H,14-16,18H2,1H3,(H,28,33) OMZXAEPYOCEHIS-UHFFFAOYSA-N 408740 N-[(2-fluorophenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 62::US11001578, Example 62::US11084809, Example 62::US11198691, Example 62 Plasma kallikrein Human 572 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408740 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408740&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365055 406799371 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073101 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1ccccc1F InChI=1S/C26H25FN4O3/c1-34-18-24-22(26(33)28-14-21-6-2-3-7-23(21)27)17-31(29-24)16-20-11-9-19(10-12-20)15-30-13-5-4-8-25(30)32/h2-13,17H,14-16,18H2,1H3,(H,28,33) OMZXAEPYOCEHIS-UHFFFAOYSA-N 408740 N-[(2-fluorophenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 62::US11001578, Example 62::US11084809, Example 62::US11198691, Example 62 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408740 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408740&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365055 406799371 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073102 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1ccccc1C(F)(F)F InChI=1S/C27H25F3N4O3/c1-37-18-24-22(26(36)31-14-21-6-2-3-7-23(21)27(28,29)30)17-34(32-24)16-20-11-9-19(10-12-20)15-33-13-5-4-8-25(33)35/h2-13,17H,14-16,18H2,1H3,(H,31,36) ZLZZEINFXWKIBR-UHFFFAOYSA-N 408742 3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)-N-{[2- (trifluoromethyl)phenyl]methyl}pyrazole-4-carboxamide::US10364238, Example 63::US11001578, Example 63::US11084809, Example 63::US11198691, Example 63 Plasma kallikrein Human 342 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408742 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408742&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365012 406799373 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073103 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1ccccc1C(F)(F)F InChI=1S/C27H25F3N4O3/c1-37-18-24-22(26(36)31-14-21-6-2-3-7-23(21)27(28,29)30)17-34(32-24)16-20-11-9-19(10-12-20)15-33-13-5-4-8-25(33)35/h2-13,17H,14-16,18H2,1H3,(H,31,36) ZLZZEINFXWKIBR-UHFFFAOYSA-N 408742 3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)-N-{[2- (trifluoromethyl)phenyl]methyl}pyrazole-4-carboxamide::US10364238, Example 63::US11001578, Example 63::US11084809, Example 63::US11198691, Example 63 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408742 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408742&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365012 406799373 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073104 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cc(OC)ccc1F InChI=1S/C27H27FN4O4/c1-35-18-25-23(27(34)29-14-21-13-22(36-2)10-11-24(21)28)17-32(30-25)16-20-8-6-19(7-9-20)15-31-12-4-3-5-26(31)33/h3-13,17H,14-16,18H2,1-2H3,(H,29,34) NKTZDNHYVJSOOU-UHFFFAOYSA-N 408744 N-[(2-fluoro-5-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide::US10364238, Example 64::US11001578, Example 64::US11084809, Example 64::US11198691, Example 64 Plasma kallikrein Human 35.2 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408744 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408744&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365036 406799375 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073105 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cc(OC)ccc1F InChI=1S/C27H27FN4O4/c1-35-18-25-23(27(34)29-14-21-13-22(36-2)10-11-24(21)28)17-32(30-25)16-20-8-6-19(7-9-20)15-31-12-4-3-5-26(31)33/h3-13,17H,14-16,18H2,1-2H3,(H,29,34) NKTZDNHYVJSOOU-UHFFFAOYSA-N 408744 N-[(2-fluoro-5-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide::US10364238, Example 64::US11001578, Example 64::US11084809, Example 64::US11198691, Example 64 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408744 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408744&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365036 406799375 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073106 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1ccc(C)cc1F InChI=1S/C27H27FN4O3/c1-19-6-11-22(24(28)13-19)14-29-27(34)23-17-32(30-25(23)18-35-2)16-21-9-7-20(8-10-21)15-31-12-4-3-5-26(31)33/h3-13,17H,14-16,18H2,1-2H3,(H,29,34) XRBNFAVKAJTXOR-UHFFFAOYSA-N 408745 N-[(2-fluoro-4-methylphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 65::US11001578, Example 65::US11084809, Example 65::US11198691, Example 65 Plasma kallikrein Human 43.3 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408745 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408745&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365028 406799376 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073107 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1ccc(C)cc1F InChI=1S/C27H27FN4O3/c1-19-6-11-22(24(28)13-19)14-29-27(34)23-17-32(30-25(23)18-35-2)16-21-9-7-20(8-10-21)15-31-12-4-3-5-26(31)33/h3-13,17H,14-16,18H2,1-2H3,(H,29,34) XRBNFAVKAJTXOR-UHFFFAOYSA-N 408745 N-[(2-fluoro-4-methylphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 65::US11001578, Example 65::US11084809, Example 65::US11198691, Example 65 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408745 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408745&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365028 406799376 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073108 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1c(F)ccc(OC)c1F InChI=1S/C27H26F2N4O4/c1-36-17-23-21(27(35)30-13-20-22(28)10-11-24(37-2)26(20)29)16-33(31-23)15-19-8-6-18(7-9-19)14-32-12-4-3-5-25(32)34/h3-12,16H,13-15,17H2,1-2H3,(H,30,35) PIYDGHWVVUCTNS-UHFFFAOYSA-N 408746 N-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin- 1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide::US10364238, Example 66::US10730874, Example 00395::US11001578, Example 66::US11084809, Example 66::US11198691, Example 66::US11352356, Table II.1 Plasma kallikrein Human 4.60 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408746 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408746&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365096 406799377 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073109 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1c(F)ccc(OC)c1F InChI=1S/C27H26F2N4O4/c1-36-17-23-21(27(35)30-13-20-22(28)10-11-24(37-2)26(20)29)16-33(31-23)15-19-8-6-18(7-9-19)14-32-12-4-3-5-25(32)34/h3-12,16H,13-15,17H2,1-2H3,(H,30,35) PIYDGHWVVUCTNS-UHFFFAOYSA-N 408746 N-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin- 1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide::US10364238, Example 66::US10730874, Example 00395::US11001578, Example 66::US11084809, Example 66::US11198691, Example 66::US11352356, Table II.1 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408746 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408746&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365096 406799377 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073110 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cc(Cl)cc(OC)c1 InChI=1S/C27H27ClN4O4/c1-35-18-25-24(27(34)29-14-21-11-22(28)13-23(12-21)36-2)17-32(30-25)16-20-8-6-19(7-9-20)15-31-10-4-3-5-26(31)33/h3-13,17H,14-16,18H2,1-2H3,(H,29,34) OABPMYGSJQVQPN-UHFFFAOYSA-N 408747 N-[(3-chloro-5-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 67::US11001578, Example 67::US11084809, Example 67::US11198691, Example 67 Plasma kallikrein Human 393 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408747 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408747&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365024 406799378 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073111 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cc(Cl)cc(OC)c1 InChI=1S/C27H27ClN4O4/c1-35-18-25-24(27(34)29-14-21-11-22(28)13-23(12-21)36-2)17-32(30-25)16-20-8-6-19(7-9-20)15-31-10-4-3-5-26(31)33/h3-13,17H,14-16,18H2,1-2H3,(H,29,34) OABPMYGSJQVQPN-UHFFFAOYSA-N 408747 N-[(3-chloro-5-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 67::US11001578, Example 67::US11084809, Example 67::US11198691, Example 67 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408747 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408747&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365024 406799378 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073112 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1ccccc1C(F)F InChI=1S/C27H26F2N4O3/c1-36-18-24-23(27(35)30-14-21-6-2-3-7-22(21)26(28)29)17-33(31-24)16-20-11-9-19(10-12-20)15-32-13-5-4-8-25(32)34/h2-13,17,26H,14-16,18H2,1H3,(H,30,35) GEFVFTYILHWIGO-UHFFFAOYSA-N 408749 N-{[2-(difluoromethyl)phenyl]methyl}-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 68::US11001578, Example 68::US11084809, Example 68::US11198691, Example 68 Plasma kallikrein Human 81.1 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408749 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408749&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365084 406799380 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073113 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1ccccc1C(F)F InChI=1S/C27H26F2N4O3/c1-36-18-24-23(27(35)30-14-21-6-2-3-7-22(21)26(28)29)17-33(31-24)16-20-11-9-19(10-12-20)15-32-13-5-4-8-25(32)34/h2-13,17,26H,14-16,18H2,1H3,(H,30,35) GEFVFTYILHWIGO-UHFFFAOYSA-N 408749 N-{[2-(difluoromethyl)phenyl]methyl}-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 68::US11001578, Example 68::US11084809, Example 68::US11198691, Example 68 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408749 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408749&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365084 406799380 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073114 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cccc(OC)c1C(F)F InChI=1S/C28H28F2N4O4/c1-37-18-23-22(28(36)31-14-21-6-5-7-24(38-2)26(21)27(29)30)17-34(32-23)16-20-11-9-19(10-12-20)15-33-13-4-3-8-25(33)35/h3-13,17,27H,14-16,18H2,1-2H3,(H,31,36) PTXDNBVAMADNIH-UHFFFAOYSA-N 408750 N-{[2-(difluoromethyl)-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-({4-[(2- oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 69::US11001578, Example 69::US11084809, Example 69::US11198691, Example 69 Plasma kallikrein Human 16.8 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408750 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408750&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365140 406799381 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073115 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cccc(OC)c1C(F)F InChI=1S/C28H28F2N4O4/c1-37-18-23-22(28(36)31-14-21-6-5-7-24(38-2)26(21)27(29)30)17-34(32-23)16-20-11-9-19(10-12-20)15-33-13-4-3-8-25(33)35/h3-13,17,27H,14-16,18H2,1-2H3,(H,31,36) PTXDNBVAMADNIH-UHFFFAOYSA-N 408750 N-{[2-(difluoromethyl)-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-({4-[(2- oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 69::US11001578, Example 69::US11084809, Example 69::US11198691, Example 69 Kallikrein-1 Human >40000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408750 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408750&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365140 406799381 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073116 Nc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1c(F)cccc1C(F)(F)F InChI=1S/C25H21F4N5O2/c26-21-5-3-4-20(25(27,28)29)18(21)12-31-24(36)19-15-34(32-23(19)30)14-17-9-7-16(8-10-17)13-33-11-2-1-6-22(33)35/h1-11,15H,12-14H2,(H2,30,32)(H,31,36) ZRDGSEIHHBOARU-UHFFFAOYSA-N 408753 3-amino-N-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 70::US11001578, Example 70::US11084809, Example 70::US11198691, Example 70 Plasma kallikrein Human 26.7 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408753 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408753&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365067 406799384 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073117 Nc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1c(F)cccc1C(F)(F)F InChI=1S/C25H21F4N5O2/c26-21-5-3-4-20(25(27,28)29)18(21)12-31-24(36)19-15-34(32-23(19)30)14-17-9-7-16(8-10-17)13-33-11-2-1-6-22(33)35/h1-11,15H,12-14H2,(H2,30,32)(H,31,36) ZRDGSEIHHBOARU-UHFFFAOYSA-N 408753 3-amino-N-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 70::US11001578, Example 70::US11084809, Example 70::US11198691, Example 70 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408753 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408753&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365067 406799384 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073118 COc1cccc(CNC(=O)c2cn(Cc3ccc(Cn4ccccc4=O)cc3)nc2NC(C)=O)c1F InChI=1S/C27H26FN5O4/c1-18(34)30-26-22(27(36)29-14-21-6-5-7-23(37-2)25(21)28)17-33(31-26)16-20-11-9-19(10-12-20)15-32-13-4-3-8-24(32)35/h3-13,17H,14-16H2,1-2H3,(H,29,36)(H,30,31,34) JJEXYMJFQVLENB-UHFFFAOYSA-N 408755 3-acetamido-N-[(2-fluoro-3-methoxyphenyl)methyl]-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 71::US11001578, Example 71::US11084809, Example 71::US11198691, Example 71 Plasma kallikrein Human 300 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408755 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408755&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365125 406799386 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073119 COc1cccc(CNC(=O)c2cn(Cc3ccc(Cn4ccccc4=O)cc3)nc2NC(C)=O)c1F InChI=1S/C27H26FN5O4/c1-18(34)30-26-22(27(36)29-14-21-6-5-7-23(37-2)25(21)28)17-33(31-26)16-20-11-9-19(10-12-20)15-32-13-4-3-8-24(32)35/h3-13,17H,14-16H2,1-2H3,(H,29,36)(H,30,31,34) JJEXYMJFQVLENB-UHFFFAOYSA-N 408755 3-acetamido-N-[(2-fluoro-3-methoxyphenyl)methyl]-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 71::US11001578, Example 71::US11084809, Example 71::US11198691, Example 71 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408755 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408755&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365125 406799386 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073120 COc1cccc(CNC(=O)c2cn(Cc3ccc(Cn4ccccc4=O)cc3)nc2N(C)C(C)=O)c1F InChI=1S/C28H28FN5O4/c1-19(35)32(2)27-23(28(37)30-15-22-7-6-8-24(38-3)26(22)29)18-34(31-27)17-21-12-10-20(11-13-21)16-33-14-5-4-9-25(33)36/h4-14,18H,15-17H2,1-3H3,(H,30,37) QWMQDDAFZVHSLS-UHFFFAOYSA-N 408756 N-[(2-fluoro-3-methoxyphenyl)methyl]-3-(N-methylacetamido)-1-({4-[(2-oxopyridin- 1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 72::US11001578, Example 72::US11084809, Example 72::US11198691, Example 72 Plasma kallikrein Human 6610 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408756 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408756&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365011 406799387 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073121 COc1cccc(CNC(=O)c2cn(Cc3ccc(Cn4ccccc4=O)cc3)nc2N(C)C(C)=O)c1F InChI=1S/C28H28FN5O4/c1-19(35)32(2)27-23(28(37)30-15-22-7-6-8-24(38-3)26(22)29)18-34(31-27)17-21-12-10-20(11-13-21)16-33-14-5-4-9-25(33)36/h4-14,18H,15-17H2,1-3H3,(H,30,37) QWMQDDAFZVHSLS-UHFFFAOYSA-N 408756 N-[(2-fluoro-3-methoxyphenyl)methyl]-3-(N-methylacetamido)-1-({4-[(2-oxopyridin- 1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 72::US11001578, Example 72::US11084809, Example 72::US11198691, Example 72 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408756 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408756&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365011 406799387 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073122 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1c(F)ccc(Cl)c1F InChI=1S/C26H23ClF2N4O3/c1-36-16-23-20(26(35)30-12-19-22(28)10-9-21(27)25(19)29)15-33(31-23)14-18-7-5-17(6-8-18)13-32-11-3-2-4-24(32)34/h2-11,15H,12-14,16H2,1H3,(H,30,35) ZHIGUNZKTJKAFE-UHFFFAOYSA-N 408757 N-[(3-chloro-2,6-difluorophenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 73::US11001578, Example 73::US11084809, Example 73::US11198691, Example 73 Plasma kallikrein Human 120 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408757 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408757&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365124 406799388 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073123 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1c(F)ccc(Cl)c1F InChI=1S/C26H23ClF2N4O3/c1-36-16-23-20(26(35)30-12-19-22(28)10-9-21(27)25(19)29)15-33(31-23)14-18-7-5-17(6-8-18)13-32-11-3-2-4-24(32)34/h2-11,15H,12-14,16H2,1H3,(H,30,35) ZHIGUNZKTJKAFE-UHFFFAOYSA-N 408757 N-[(3-chloro-2,6-difluorophenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 73::US11001578, Example 73::US11084809, Example 73::US11198691, Example 73 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408757 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408757&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365124 406799388 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073124 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cc(Cl)ccc1C#N InChI=1S/C27H24ClN5O3/c1-36-18-25-24(27(35)30-14-22-12-23(28)10-9-21(22)13-29)17-33(31-25)16-20-7-5-19(6-8-20)15-32-11-3-2-4-26(32)34/h2-12,17H,14-16,18H2,1H3,(H,30,35) AQJYHYPGWCFTGU-UHFFFAOYSA-N 408759 N-[(5-chloro-2-cyanophenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 76::US11001578, Example 76::US11084809, Example 76::US11198691, Example 76 Plasma kallikrein Human 28.3 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408759 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408759&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365097 406799390 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073125 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cc(Cl)ccc1C#N InChI=1S/C27H24ClN5O3/c1-36-18-25-24(27(35)30-14-22-12-23(28)10-9-21(22)13-29)17-33(31-25)16-20-7-5-19(6-8-20)15-32-11-3-2-4-26(32)34/h2-12,17H,14-16,18H2,1H3,(H,30,35) AQJYHYPGWCFTGU-UHFFFAOYSA-N 408759 N-[(5-chloro-2-cyanophenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 76::US11001578, Example 76::US11084809, Example 76::US11198691, Example 76 Kallikrein-1 Human >40000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408759 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408759&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365097 406799390 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073126 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1c(F)c(OC)ccc1C#N InChI=1S/C28H26FN5O4/c1-37-18-24-23(28(36)31-14-22-21(13-30)10-11-25(38-2)27(22)29)17-34(32-24)16-20-8-6-19(7-9-20)15-33-12-4-3-5-26(33)35/h3-12,17H,14-16,18H2,1-2H3,(H,31,36) SPXOTFDBWDBJRN-UHFFFAOYSA-N 408768 N-[(6-cyano-2-fluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-::US10364238, Example 77::US10730874, Example 00398::US11001578, Example 77::US11084809, Example 77::US11198691, Example 77::US11352356, Table II.4 Plasma kallikrein Human 0.600 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408768 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408768&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365006 406799399 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073127 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1c(F)c(OC)ccc1C#N InChI=1S/C28H26FN5O4/c1-37-18-24-23(28(36)31-14-22-21(13-30)10-11-25(38-2)27(22)29)17-34(32-24)16-20-8-6-19(7-9-20)15-33-12-4-3-5-26(33)35/h3-12,17H,14-16,18H2,1-2H3,(H,31,36) SPXOTFDBWDBJRN-UHFFFAOYSA-N 408768 N-[(6-cyano-2-fluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-::US10364238, Example 77::US10730874, Example 00398::US11001578, Example 77::US11084809, Example 77::US11198691, Example 77::US11352356, Table II.4 Kallikrein-1 Human >40000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408768 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408768&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365006 406799399 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073128 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cccc(OC)c1C(F)(F)F InChI=1S/C28H27F3N4O4/c1-38-18-23-22(27(37)32-14-21-6-5-7-24(39-2)26(21)28(29,30)31)17-35(33-23)16-20-11-9-19(10-12-20)15-34-13-4-3-8-25(34)36/h3-13,17H,14-16,18H2,1-2H3,(H,32,37) LSXBZEBSXFDZEZ-UHFFFAOYSA-N 408769 N-{[3-methoxy-2-(trifluoromethyl)phenyl]methyl}-3-(methoxymethyl)-1-({4-[(2- oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 78::US11001578, Example 78::US11084809, Example 78::US11198691, Example 78 Plasma kallikrein Human 612 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408769 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408769&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365105 406799400 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073129 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cccc(OC)c1C(F)(F)F InChI=1S/C28H27F3N4O4/c1-38-18-23-22(27(37)32-14-21-6-5-7-24(39-2)26(21)28(29,30)31)17-35(33-23)16-20-11-9-19(10-12-20)15-34-13-4-3-8-25(34)36/h3-13,17H,14-16,18H2,1-2H3,(H,32,37) LSXBZEBSXFDZEZ-UHFFFAOYSA-N 408769 N-{[3-methoxy-2-(trifluoromethyl)phenyl]methyl}-3-(methoxymethyl)-1-({4-[(2- oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 78::US11001578, Example 78::US11084809, Example 78::US11198691, Example 78 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408769 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408769&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365105 406799400 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073130 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cc(OC)ccc1C(F)(F)F InChI=1S/C28H27F3N4O4/c1-38-18-25-23(27(37)32-14-21-13-22(39-2)10-11-24(21)28(29,30)31)17-35(33-25)16-20-8-6-19(7-9-20)15-34-12-4-3-5-26(34)36/h3-13,17H,14-16,18H2,1-2H3,(H,32,37) FKGBWMYRUOPIHY-UHFFFAOYSA-N 408770 N-{[5-methoxy-2-(trifluoromethyl)phenyl]methyl}-3-(methoxymethyl)-1-({4-[(2- oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 79::US11001578, Example 79::US11084809, Example 79::US11198691, Example 79 Plasma kallikrein Human 14.7 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408770 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408770&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365060 406799401 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073131 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cc(OC)ccc1C(F)(F)F InChI=1S/C28H27F3N4O4/c1-38-18-25-23(27(37)32-14-21-13-22(39-2)10-11-24(21)28(29,30)31)17-35(33-25)16-20-8-6-19(7-9-20)15-34-12-4-3-5-26(34)36/h3-13,17H,14-16,18H2,1-2H3,(H,32,37) FKGBWMYRUOPIHY-UHFFFAOYSA-N 408770 N-{[5-methoxy-2-(trifluoromethyl)phenyl]methyl}-3-(methoxymethyl)-1-({4-[(2- oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 79::US11001578, Example 79::US11084809, Example 79::US11198691, Example 79 Kallikrein-1 Human >40000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408770 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408770&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365060 406799401 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073132 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1c(F)cccc1C(F)F InChI=1S/C27H25F3N4O3/c1-37-17-24-22(27(36)31-13-21-20(26(29)30)5-4-6-23(21)28)16-34(32-24)15-19-10-8-18(9-11-19)14-33-12-3-2-7-25(33)35/h2-12,16,26H,13-15,17H2,1H3,(H,31,36) BZFADXUGNHDNKB-UHFFFAOYSA-N 408772 N-{[2-(difluoromethyl)-6-fluorophenyl]methyl}-3-(methoxymethyl)-1-({4-[(2- oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 80::US11001578, Example 80::US11084809, Example 80::US11198691, Example 80 Plasma kallikrein Human 20.4 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408772 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408772&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365145 406799403 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073133 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1c(F)cccc1C(F)F InChI=1S/C27H25F3N4O3/c1-37-17-24-22(27(36)31-13-21-20(26(29)30)5-4-6-23(21)28)16-34(32-24)15-19-10-8-18(9-11-19)14-33-12-3-2-7-25(33)35/h2-12,16,26H,13-15,17H2,1H3,(H,31,36) BZFADXUGNHDNKB-UHFFFAOYSA-N 408772 N-{[2-(difluoromethyl)-6-fluorophenyl]methyl}-3-(methoxymethyl)-1-({4-[(2- oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 80::US11001578, Example 80::US11084809, Example 80::US11198691, Example 80 Kallikrein-1 Human >40000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408772 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408772&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365145 406799403 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073134 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cc(OC)ccc1C(F)F InChI=1S/C28H28F2N4O4/c1-37-18-25-24(28(36)31-14-21-13-22(38-2)10-11-23(21)27(29)30)17-34(32-25)16-20-8-6-19(7-9-20)15-33-12-4-3-5-26(33)35/h3-13,17,27H,14-16,18H2,1-2H3,(H,31,36) IBBPTWWPBCQANZ-UHFFFAOYSA-N 408773 N-{[2-(difluoromethyl)-5-methoxyphenyl]methyl}-3-(methoxymethyl)-1-({4-[(2- oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 81::US11001578, Example 81::US11084809, Example 81::US11198691, Example 81 Plasma kallikrein Human 2.30 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408773 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408773&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365102 406799404 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073135 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cc(OC)ccc1C(F)F InChI=1S/C28H28F2N4O4/c1-37-18-25-24(28(36)31-14-21-13-22(38-2)10-11-23(21)27(29)30)17-34(32-25)16-20-8-6-19(7-9-20)15-33-12-4-3-5-26(33)35/h3-13,17,27H,14-16,18H2,1-2H3,(H,31,36) IBBPTWWPBCQANZ-UHFFFAOYSA-N 408773 N-{[2-(difluoromethyl)-5-methoxyphenyl]methyl}-3-(methoxymethyl)-1-({4-[(2- oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 81::US11001578, Example 81::US11084809, Example 81::US11198691, Example 81 Kallikrein-1 Human >40000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408773 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408773&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365102 406799404 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073136 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1c(F)ccc(OC)c1C(F)F InChI=1S/C28H27F3N4O4/c1-38-17-23-21(28(37)32-13-20-22(29)10-11-24(39-2)26(20)27(30)31)16-35(33-23)15-19-8-6-18(7-9-19)14-34-12-4-3-5-25(34)36/h3-12,16,27H,13-15,17H2,1-2H3,(H,32,37) FDDKVGBGYLYHDV-UHFFFAOYSA-N 408775 N-{[2-(difluoromethyl)-6-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-({4- [(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 83::US11001578, Example 83::US11084809, Example 83::US11198691, Example 83 Plasma kallikrein Human 6.80 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408775 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408775&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365138 406799406 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073137 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1c(F)ccc(OC)c1C(F)F InChI=1S/C28H27F3N4O4/c1-38-17-23-21(28(37)32-13-20-22(29)10-11-24(39-2)26(20)27(30)31)16-35(33-23)15-19-8-6-18(7-9-19)14-34-12-4-3-5-25(34)36/h3-12,16,27H,13-15,17H2,1-2H3,(H,32,37) FDDKVGBGYLYHDV-UHFFFAOYSA-N 408775 N-{[2-(difluoromethyl)-6-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-({4- [(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 83::US11001578, Example 83::US11084809, Example 83::US11198691, Example 83 Kallikrein-1 Human >40000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408775 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408775&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365138 406799406 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073138 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1c(F)cccc1C(N)=O InChI=1S/C27H26FN5O4/c1-37-17-24-22(27(36)30-13-21-20(26(29)35)5-4-6-23(21)28)16-33(31-24)15-19-10-8-18(9-11-19)14-32-12-3-2-7-25(32)34/h2-12,16H,13-15,17H2,1H3,(H2,29,35)(H,30,36) PQVWIESRTSEZPB-UHFFFAOYSA-N 408778 N-[(2-carbamoyl-6-fluorophenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 85::US11001578, Example 85::US11084809, Example 85::US11198691, Example 85 Plasma kallikrein Human 79.2 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408778 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408778&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365001 406799409 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073139 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1c(F)cccc1C(N)=O InChI=1S/C27H26FN5O4/c1-37-17-24-22(27(36)30-13-21-20(26(29)35)5-4-6-23(21)28)16-33(31-24)15-19-10-8-18(9-11-19)14-32-12-3-2-7-25(32)34/h2-12,16H,13-15,17H2,1H3,(H2,29,35)(H,30,36) PQVWIESRTSEZPB-UHFFFAOYSA-N 408778 N-[(2-carbamoyl-6-fluorophenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 85::US11001578, Example 85::US11084809, Example 85::US11198691, Example 85 Kallikrein-1 Human >40000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408778 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408778&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365001 406799409 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073140 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cc(OC)ccc1C(N)=O InChI=1S/C28H29N5O5/c1-37-18-25-24(28(36)30-14-21-13-22(38-2)10-11-23(21)27(29)35)17-33(31-25)16-20-8-6-19(7-9-20)15-32-12-4-3-5-26(32)34/h3-13,17H,14-16,18H2,1-2H3,(H2,29,35)(H,30,36) VTFAEOJNECOMFY-UHFFFAOYSA-N 408779 N-[(2-carbamoyl-5-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin- 1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 86::US11001578, Example 86::US11084809, Example 86::US11198691, Example 86 Plasma kallikrein Human 8.70 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408779 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408779&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365131 406799410 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073141 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cc(OC)ccc1C(N)=O InChI=1S/C28H29N5O5/c1-37-18-25-24(28(36)30-14-21-13-22(38-2)10-11-23(21)27(29)35)17-33(31-25)16-20-8-6-19(7-9-20)15-32-12-4-3-5-26(32)34/h3-13,17H,14-16,18H2,1-2H3,(H2,29,35)(H,30,36) VTFAEOJNECOMFY-UHFFFAOYSA-N 408779 N-[(2-carbamoyl-5-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin- 1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 86::US11001578, Example 86::US11084809, Example 86::US11198691, Example 86 Kallikrein-1 Human >40000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408779 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408779&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365131 406799410 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073142 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1ccccc1C(O)=O InChI=1S/C27H26N4O5/c1-36-18-24-23(26(33)28-14-21-6-2-3-7-22(21)27(34)35)17-31(29-24)16-20-11-9-19(10-12-20)15-30-13-5-4-8-25(30)32/h2-13,17H,14-16,18H2,1H3,(H,28,33)(H,34,35) MCBMZYKZJXHUKZ-UHFFFAOYSA-N 408780 2-({[3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazol-4- yl]formamido}methyl)benzoic acid ::US10364238, Example 87::US11001578, Example 87::US11084809, Example 87::US11198691, Example 87 Plasma kallikrein Human >10000 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408780 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408780&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365095 406799411 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073143 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1ccccc1C(O)=O InChI=1S/C27H26N4O5/c1-36-18-24-23(26(33)28-14-21-6-2-3-7-22(21)27(34)35)17-31(29-24)16-20-11-9-19(10-12-20)15-30-13-5-4-8-25(30)32/h2-13,17H,14-16,18H2,1H3,(H,28,33)(H,34,35) MCBMZYKZJXHUKZ-UHFFFAOYSA-N 408780 2-({[3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazol-4- yl]formamido}methyl)benzoic acid ::US10364238, Example 87::US11001578, Example 87::US11084809, Example 87::US11198691, Example 87 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408780 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408780&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365095 406799411 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073144 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cccc(OC(F)F)c1F InChI=1S/C27H25F3N4O4/c1-37-17-22-21(26(36)31-13-20-5-4-6-23(25(20)28)38-27(29)30)16-34(32-22)15-19-10-8-18(9-11-19)14-33-12-3-2-7-24(33)35/h2-12,16,27H,13-15,17H2,1H3,(H,31,36) CMNOMOOEIDZWNA-UHFFFAOYSA-N 408781 N-{[3-(difluoromethoxy)-2-fluorophenyl]methyl}-3-(methoxymethyl)-1-({4-[(2- oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 90::US11001578, Example 90::US11084809, Example 90::US11198691, Example 90 Plasma kallikrein Human 154 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408781 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408781&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365051 406799412 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073145 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cccc(OC(F)F)c1F InChI=1S/C27H25F3N4O4/c1-37-17-22-21(26(36)31-13-20-5-4-6-23(25(20)28)38-27(29)30)16-34(32-22)15-19-10-8-18(9-11-19)14-33-12-3-2-7-24(33)35/h2-12,16,27H,13-15,17H2,1H3,(H,31,36) CMNOMOOEIDZWNA-UHFFFAOYSA-N 408781 N-{[3-(difluoromethoxy)-2-fluorophenyl]methyl}-3-(methoxymethyl)-1-({4-[(2- oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 90::US11001578, Example 90::US11084809, Example 90::US11198691, Example 90 Kallikrein-1 Human >40000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408781 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408781&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365051 406799412 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073146 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cccc(OC(F)F)c1 InChI=1S/C27H26F2N4O4/c1-36-18-24-23(26(35)30-14-21-5-4-6-22(13-21)37-27(28)29)17-33(31-24)16-20-10-8-19(9-11-20)15-32-12-3-2-7-25(32)34/h2-13,17,27H,14-16,18H2,1H3,(H,30,35) ZLXXVTBIWCEPEY-UHFFFAOYSA-N 408782 N-{[3-(difluoromethoxy)phenyl]methyl}-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 91::US11001578, Example 91::US11084809, Example 91::US11198691, Example 91 Plasma kallikrein Human 523 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408782 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408782&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365090 406799413 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073147 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cccc(OC(F)F)c1 InChI=1S/C27H26F2N4O4/c1-36-18-24-23(26(35)30-14-21-5-4-6-22(13-21)37-27(28)29)17-33(31-24)16-20-10-8-19(9-11-20)15-32-12-3-2-7-25(32)34/h2-13,17,27H,14-16,18H2,1H3,(H,30,35) ZLXXVTBIWCEPEY-UHFFFAOYSA-N 408782 N-{[3-(difluoromethoxy)phenyl]methyl}-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 91::US11001578, Example 91::US11084809, Example 91::US11198691, Example 91 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408782 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408782&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365090 406799413 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073148 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1c(F)cccc1OC(F)F InChI=1S/C27H25F3N4O4/c1-37-17-23-21(26(36)31-13-20-22(28)5-4-6-24(20)38-27(29)30)16-34(32-23)15-19-10-8-18(9-11-19)14-33-12-3-2-7-25(33)35/h2-12,16,27H,13-15,17H2,1H3,(H,31,36) MKZIFUOKFBQCJL-UHFFFAOYSA-N 408783 N-{[2-(difluoromethoxy)-6-fluorophenyl]methyl}-3-(methoxymethyl)-1-({4-[(2- oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 92::US11001578, Example 92::US11084809, Example 92::US11198691, Example 92 Plasma kallikrein Human 16.0 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408783 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408783&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365108 406799414 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073149 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1c(F)cccc1OC(F)F InChI=1S/C27H25F3N4O4/c1-37-17-23-21(26(36)31-13-20-22(28)5-4-6-24(20)38-27(29)30)16-34(32-23)15-19-10-8-18(9-11-19)14-33-12-3-2-7-25(33)35/h2-12,16,27H,13-15,17H2,1H3,(H,31,36) MKZIFUOKFBQCJL-UHFFFAOYSA-N 408783 N-{[2-(difluoromethoxy)-6-fluorophenyl]methyl}-3-(methoxymethyl)-1-({4-[(2- oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 92::US11001578, Example 92::US11084809, Example 92::US11198691, Example 92 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408783 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408783&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365108 406799414 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073150 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cc(F)ccc1F InChI=1S/C26H24F2N4O3/c1-35-17-24-22(26(34)29-13-20-12-21(27)9-10-23(20)28)16-32(30-24)15-19-7-5-18(6-8-19)14-31-11-3-2-4-25(31)33/h2-12,16H,13-15,17H2,1H3,(H,29,34) XQLOPLZHIJLNDB-UHFFFAOYSA-N 408784 N-[(2,5-difluorophenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide::US10364238, Example 94::US11001578, Example 94::US11084809, Example 94::US11198691, Example 94 Plasma kallikrein Human 780 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408784 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408784&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365078 406799415 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073151 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cc(F)ccc1F InChI=1S/C26H24F2N4O3/c1-35-17-24-22(26(34)29-13-20-12-21(27)9-10-23(20)28)16-32(30-24)15-19-7-5-18(6-8-19)14-31-11-3-2-4-25(31)33/h2-12,16H,13-15,17H2,1H3,(H,29,34) XQLOPLZHIJLNDB-UHFFFAOYSA-N 408784 N-[(2,5-difluorophenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide::US10364238, Example 94::US11001578, Example 94::US11084809, Example 94::US11198691, Example 94 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408784 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408784&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365078 406799415 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073152 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cc(F)cc(OC)c1 InChI=1S/C27H27FN4O4/c1-35-18-25-24(27(34)29-14-21-11-22(28)13-23(12-21)36-2)17-32(30-25)16-20-8-6-19(7-9-20)15-31-10-4-3-5-26(31)33/h3-13,17H,14-16,18H2,1-2H3,(H,29,34) AYOVCXXHHIWMRN-UHFFFAOYSA-N 408786 N-[(3-fluoro-5-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 95::US11001578, Example 95::US11084809, Example 95::US11198691, Example 95 Plasma kallikrein Human 308 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408786 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408786&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365039 406799417 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073153 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cc(F)cc(OC)c1 InChI=1S/C27H27FN4O4/c1-35-18-25-24(27(34)29-14-21-11-22(28)13-23(12-21)36-2)17-32(30-25)16-20-8-6-19(7-9-20)15-31-10-4-3-5-26(31)33/h3-13,17H,14-16,18H2,1-2H3,(H,29,34) AYOVCXXHHIWMRN-UHFFFAOYSA-N 408786 N-[(3-fluoro-5-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 95::US11001578, Example 95::US11084809, Example 95::US11198691, Example 95 Kallikrein-1 Human >40000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408786 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408786&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365039 406799417 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073154 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cc(F)cc(OC)c1F InChI=1S/C27H26F2N4O4/c1-36-17-23-22(27(35)30-13-20-11-21(28)12-24(37-2)26(20)29)16-33(31-23)15-19-8-6-18(7-9-19)14-32-10-4-3-5-25(32)34/h3-12,16H,13-15,17H2,1-2H3,(H,30,35) FKXBPOXUNOOPGU-UHFFFAOYSA-N 408787 N-[(2,5-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin- 1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 96::US11001578, Example 96::US11084809, Example 96::US11198691, Example 96 Plasma kallikrein Human 75.0 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408787 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408787&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365093 406799418 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073155 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cc(F)cc(OC)c1F InChI=1S/C27H26F2N4O4/c1-36-17-23-22(27(35)30-13-20-11-21(28)12-24(37-2)26(20)29)16-33(31-23)15-19-8-6-18(7-9-19)14-32-10-4-3-5-25(32)34/h3-12,16H,13-15,17H2,1-2H3,(H,30,35) FKXBPOXUNOOPGU-UHFFFAOYSA-N 408787 N-[(2,5-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin- 1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 96::US11001578, Example 96::US11084809, Example 96::US11198691, Example 96 Kallikrein-1 Human >40000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408787 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408787&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365093 406799418 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073156 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1c(C)cccc1F InChI=1S/C27H27FN4O3/c1-19-6-5-7-24(28)22(19)14-29-27(34)23-17-32(30-25(23)18-35-2)16-21-11-9-20(10-12-21)15-31-13-4-3-8-26(31)33/h3-13,17H,14-16,18H2,1-2H3,(H,29,34) NLVINHRIZCLAQG-UHFFFAOYSA-N 408788 N-[(2-fluoro-6-methylphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide::US10364238, Example 97::US11001578, Example 97::US11084809, Example 97::US11198691, Example 97 Plasma kallikrein Human 153 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408788 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408788&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365111 406799419 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073157 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1c(C)cccc1F InChI=1S/C27H27FN4O3/c1-19-6-5-7-24(28)22(19)14-29-27(34)23-17-32(30-25(23)18-35-2)16-21-11-9-20(10-12-21)15-31-13-4-3-8-26(31)33/h3-13,17H,14-16,18H2,1-2H3,(H,29,34) NLVINHRIZCLAQG-UHFFFAOYSA-N 408788 N-[(2-fluoro-6-methylphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide::US10364238, Example 97::US11001578, Example 97::US11084809, Example 97::US11198691, Example 97 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408788 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408788&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365111 406799419 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073158 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1c(Cl)ccc(OC)c1F InChI=1S/C27H26ClFN4O4/c1-36-17-23-21(27(35)30-13-20-22(28)10-11-24(37-2)26(20)29)16-33(31-23)15-19-8-6-18(7-9-19)14-32-12-4-3-5-25(32)34/h3-12,16H,13-15,17H2,1-2H3,(H,30,35) AJVITEJNDAKYPL-UHFFFAOYSA-N 497307 N-[(6-chloro-2-fluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-::US11001578, Example 99::US11084809, Example 99::US11198691, Example 99 Plasma kallikrein Human 6.40 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=497307 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=497307&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365144 459070294 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073159 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1c(Cl)ccc(OC)c1F InChI=1S/C27H26ClFN4O4/c1-36-17-23-21(27(35)30-13-20-22(28)10-11-24(37-2)26(20)29)16-33(31-23)15-19-8-6-18(7-9-19)14-32-12-4-3-5-25(32)34/h3-12,16H,13-15,17H2,1-2H3,(H,30,35) AJVITEJNDAKYPL-UHFFFAOYSA-N 497307 N-[(6-chloro-2-fluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-::US11001578, Example 99::US11084809, Example 99::US11198691, Example 99 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=497307 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=497307&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365144 459070294 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073160 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cccc(O)c1F InChI=1S/C26H25FN4O4/c1-35-17-22-21(26(34)28-13-20-5-4-6-23(32)25(20)27)16-31(29-22)15-19-10-8-18(9-11-19)14-30-12-3-2-7-24(30)33/h2-12,16,32H,13-15,17H2,1H3,(H,28,34) JFAWWGDJBCGIDJ-UHFFFAOYSA-N 408790 N-[(2-fluoro-3-hydroxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 129::US11001578, Example 129::US11084809, Example 129::US11198691, Example 129 Plasma kallikrein Human 437 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408790 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408790&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365133 406799421 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073161 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cccc(O)c1F InChI=1S/C26H25FN4O4/c1-35-17-22-21(26(34)28-13-20-5-4-6-23(32)25(20)27)16-31(29-22)15-19-10-8-18(9-11-19)14-30-12-3-2-7-24(30)33/h2-12,16,32H,13-15,17H2,1H3,(H,28,34) JFAWWGDJBCGIDJ-UHFFFAOYSA-N 408790 N-[(2-fluoro-3-hydroxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 129::US11001578, Example 129::US11084809, Example 129::US11198691, Example 129 Kallikrein-1 Human >40000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408790 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408790&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365133 406799421 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073162 Nc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cccc(O)c1F InChI=1S/C24H22FN5O3/c25-22-18(4-3-5-20(22)31)12-27-24(33)19-15-30(28-23(19)26)14-17-9-7-16(8-10-17)13-29-11-2-1-6-21(29)32/h1-11,15,31H,12-14H2,(H2,26,28)(H,27,33) OOXKEXDZGXUAST-UHFFFAOYSA-N 408792 3-amino-N-[(2-fluoro-3-hydroxyphenyl)methyl]-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 130::US11001578, Example 130::US11084809, Example 130::US11198691, Example 130 Plasma kallikrein Human 174 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408792 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408792&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365044 406799423 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073163 Nc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cccc(O)c1F InChI=1S/C24H22FN5O3/c25-22-18(4-3-5-20(22)31)12-27-24(33)19-15-30(28-23(19)26)14-17-9-7-16(8-10-17)13-29-11-2-1-6-21(29)32/h1-11,15,31H,12-14H2,(H2,26,28)(H,27,33) OOXKEXDZGXUAST-UHFFFAOYSA-N 408792 3-amino-N-[(2-fluoro-3-hydroxyphenyl)methyl]-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 130::US11001578, Example 130::US11084809, Example 130::US11198691, Example 130 Kallikrein-1 Human >40000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408792 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408792&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365044 406799423 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073164 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1ccccc1C(=O)OC InChI=1S/C28H28N4O5/c1-36-19-25-24(27(34)29-15-22-7-3-4-8-23(22)28(35)37-2)18-32(30-25)17-21-12-10-20(11-13-21)16-31-14-6-5-9-26(31)33/h3-14,18H,15-17,19H2,1-2H3,(H,29,34) CLMIQCGDYIVGMD-UHFFFAOYSA-N 408793 methyl 2-({[3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazol-4-yl]formamido}methyl)benzoate::US10364238, Example 131::US11001578, Example 131::US11084809, Example 131::US11198691, Example 131 Plasma kallikrein Human 1510 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408793 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408793&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121364999 406799424 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073165 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1ccccc1C(=O)OC InChI=1S/C28H28N4O5/c1-36-19-25-24(27(34)29-15-22-7-3-4-8-23(22)28(35)37-2)18-32(30-25)17-21-12-10-20(11-13-21)16-31-14-6-5-9-26(31)33/h3-14,18H,15-17,19H2,1-2H3,(H,29,34) CLMIQCGDYIVGMD-UHFFFAOYSA-N 408793 methyl 2-({[3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazol-4-yl]formamido}methyl)benzoate::US10364238, Example 131::US11001578, Example 131::US11084809, Example 131::US11198691, Example 131 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408793 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408793&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121364999 406799424 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073166 CCc1cccc(CNC(=O)c2cn(Cc3ccc(Cn4ccccc4=O)cc3)nc2COC)c1F InChI=1S/C28H29FN4O3/c1-3-22-7-6-8-23(27(22)29)15-30-28(35)24-18-33(31-25(24)19-36-2)17-21-12-10-20(11-13-21)16-32-14-5-4-9-26(32)34/h4-14,18H,3,15-17,19H2,1-2H3,(H,30,35) TVACIVBKATZGQV-UHFFFAOYSA-N 408794 N-[(3-ethyl-2-fluorophenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 132::US11001578, Example 132::US11084809, Example 132::US11198691, Example 132 Plasma kallikrein Human 135 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408794 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408794&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365023 406799425 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073167 CCc1cccc(CNC(=O)c2cn(Cc3ccc(Cn4ccccc4=O)cc3)nc2COC)c1F InChI=1S/C28H29FN4O3/c1-3-22-7-6-8-23(27(22)29)15-30-28(35)24-18-33(31-25(24)19-36-2)17-21-12-10-20(11-13-21)16-32-14-5-4-9-26(32)34/h4-14,18H,3,15-17,19H2,1-2H3,(H,30,35) TVACIVBKATZGQV-UHFFFAOYSA-N 408794 N-[(3-ethyl-2-fluorophenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 132::US11001578, Example 132::US11084809, Example 132::US11198691, Example 132 Kallikrein-1 Human >40000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408794 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408794&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365023 406799425 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073168 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cccc(OC)c1 InChI=1S/C27H28N4O4/c1-34-19-25-24(27(33)28-15-22-6-5-7-23(14-22)35-2)18-31(29-25)17-21-11-9-20(10-12-21)16-30-13-4-3-8-26(30)32/h3-14,18H,15-17,19H2,1-2H3,(H,28,33) YDHZFMPDUQUAJM-UHFFFAOYSA-N 408795 3-(methoxymethyl)-N-[(3-methoxyphenyl)methyl]-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 133::US11001578, Example 133::US11084809, Example 133::US11198691, Example 133 Plasma kallikrein Human 90.2 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408795 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408795&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365129 406799426 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073169 COCc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCc1cccc(OC)c1 InChI=1S/C27H28N4O4/c1-34-19-25-24(27(33)28-15-22-6-5-7-23(14-22)35-2)18-31(29-25)17-21-11-9-20(10-12-21)16-30-13-4-3-8-26(30)32/h3-14,18H,15-17,19H2,1-2H3,(H,28,33) YDHZFMPDUQUAJM-UHFFFAOYSA-N 408795 3-(methoxymethyl)-N-[(3-methoxyphenyl)methyl]-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 133::US11001578, Example 133::US11084809, Example 133::US11198691, Example 133 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408795 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408795&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365129 406799426 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073170 COCc1nn(Cc2ccc(Cn3ccncc3=O)cc2)cc1C(=O)NCc1cccc(OC)c1F InChI=1S/C26H26FN5O4/c1-35-17-22-21(26(34)29-12-20-4-3-5-23(36-2)25(20)27)16-32(30-22)15-19-8-6-18(7-9-19)14-31-11-10-28-13-24(31)33/h3-11,13,16H,12,14-15,17H2,1-2H3,(H,29,34) QNPXQCIYWHCURP-UHFFFAOYSA-N 408796 N-[(2-fluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyrazin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 104::US11001578, Example 104::US11084809, Example 104::US11198691, Example 104 Plasma kallikrein Human 691 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408796 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408796&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365146 406799427 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073171 COCc1nn(Cc2ccc(Cn3ccncc3=O)cc2)cc1C(=O)NCc1cccc(OC)c1F InChI=1S/C26H26FN5O4/c1-35-17-22-21(26(34)29-12-20-4-3-5-23(36-2)25(20)27)16-32(30-22)15-19-8-6-18(7-9-19)14-31-11-10-28-13-24(31)33/h3-11,13,16H,12,14-15,17H2,1-2H3,(H,29,34) QNPXQCIYWHCURP-UHFFFAOYSA-N 408796 N-[(2-fluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyrazin-1- yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 104::US11001578, Example 104::US11084809, Example 104::US11198691, Example 104 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408796 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408796&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365146 406799427 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073172 COCc1nn(Cc2ccc(Cn3ccc(C)cc3=O)cc2)cc1C(=O)NCc1c(F)ccc(OC)c1F InChI=1S/C28H28F2N4O4/c1-18-10-11-33(26(35)12-18)14-19-4-6-20(7-5-19)15-34-16-22(24(32-34)17-37-2)28(36)31-13-21-23(29)8-9-25(38-3)27(21)30/h4-12,16H,13-15,17H2,1-3H3,(H,31,36) BKTJDPOLKWOBHW-UHFFFAOYSA-N 408797 N-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(4-methyl-2- oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide::US10364238, Example 106::US11001578, Example 106::US11084809, Example 106::US11198691, Example 106 Plasma kallikrein Human 140 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408797 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408797&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365091 406799428 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073173 COCc1nn(Cc2ccc(Cn3ccc(C)cc3=O)cc2)cc1C(=O)NCc1c(F)ccc(OC)c1F InChI=1S/C28H28F2N4O4/c1-18-10-11-33(26(35)12-18)14-19-4-6-20(7-5-19)15-34-16-22(24(32-34)17-37-2)28(36)31-13-21-23(29)8-9-25(38-3)27(21)30/h4-12,16H,13-15,17H2,1-3H3,(H,31,36) BKTJDPOLKWOBHW-UHFFFAOYSA-N 408797 N-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(4-methyl-2- oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide::US10364238, Example 106::US11001578, Example 106::US11084809, Example 106::US11198691, Example 106 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408797 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408797&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365091 406799428 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073174 COCc1nn(Cc2ccc(Cn3cc(F)ccc3=O)cc2)cc1C(=O)NCc1c(F)ccc(OC)c1F InChI=1S/C27H25F3N4O4/c1-37-16-23-21(27(36)31-11-20-22(29)8-9-24(38-2)26(20)30)15-34(32-23)13-18-5-3-17(4-6-18)12-33-14-19(28)7-10-25(33)35/h3-10,14-15H,11-13,16H2,1-2H3,(H,31,36) JRSJFSJQRZMHDN-UHFFFAOYSA-N 408798 N-[(2,6-difluoro-3-methoxyphenyl)methyl]-1-({4-[(5-fluoro-2-oxopyridin-1- yl)methyl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide::US10364238, Example 108::US11001578, Example 108::US11084809, Example 108::US11198691, Example 108 Plasma kallikrein Human 5.50 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408798 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408798&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365114 406799429 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073175 COCc1nn(Cc2ccc(Cn3cc(F)ccc3=O)cc2)cc1C(=O)NCc1c(F)ccc(OC)c1F InChI=1S/C27H25F3N4O4/c1-37-16-23-21(27(36)31-11-20-22(29)8-9-24(38-2)26(20)30)15-34(32-23)13-18-5-3-17(4-6-18)12-33-14-19(28)7-10-25(33)35/h3-10,14-15H,11-13,16H2,1-2H3,(H,31,36) JRSJFSJQRZMHDN-UHFFFAOYSA-N 408798 N-[(2,6-difluoro-3-methoxyphenyl)methyl]-1-({4-[(5-fluoro-2-oxopyridin-1- yl)methyl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide::US10364238, Example 108::US11001578, Example 108::US11084809, Example 108::US11198691, Example 108 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408798 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408798&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365114 406799429 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073176 CCOc1ccn(Cc2ccc(Cn3cc(C(=O)NCc4c(F)ccc(OC)c4F)c(COC)n3)cc2)c(=O)c1 InChI=1S/C29H30F2N4O5/c1-4-40-21-11-12-34(27(36)13-21)15-19-5-7-20(8-6-19)16-35-17-23(25(33-35)18-38-2)29(37)32-14-22-24(30)9-10-26(39-3)28(22)31/h5-13,17H,4,14-16,18H2,1-3H3,(H,32,37) MMGSTVOIQROITG-UHFFFAOYSA-N 408799 N-[(2,6-difluoro-3-methoxyphenyl)methyl]-1-({4-[(4-ethoxy-2-oxopyridin-1- yl)methyl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide ::US10364238, Example 109::US11001578, Example 109::US11084809, Example 109::US11198691, Example 109 Plasma kallikrein Human 2980 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408799 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408799&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121364997 406799430 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073177 CCOc1ccn(Cc2ccc(Cn3cc(C(=O)NCc4c(F)ccc(OC)c4F)c(COC)n3)cc2)c(=O)c1 InChI=1S/C29H30F2N4O5/c1-4-40-21-11-12-34(27(36)13-21)15-19-5-7-20(8-6-19)16-35-17-23(25(33-35)18-38-2)29(37)32-14-22-24(30)9-10-26(39-3)28(22)31/h5-13,17H,4,14-16,18H2,1-3H3,(H,32,37) MMGSTVOIQROITG-UHFFFAOYSA-N 408799 N-[(2,6-difluoro-3-methoxyphenyl)methyl]-1-({4-[(4-ethoxy-2-oxopyridin-1- yl)methyl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide ::US10364238, Example 109::US11001578, Example 109::US11084809, Example 109::US11198691, Example 109 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408799 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408799&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121364997 406799430 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073178 COc1cccc(CNC(=O)c2cn(Cc3ccc(Cn4ccccc4=O)cc3)c(C)n2)c1F InChI=1S/C26H25FN4O3/c1-18-29-22(26(33)28-14-21-6-5-7-23(34-2)25(21)27)17-31(18)16-20-11-9-19(10-12-20)15-30-13-4-3-8-24(30)32/h3-13,17H,14-16H2,1-2H3,(H,28,33) XCBLTBHUJNNESG-UHFFFAOYSA-N 408801 N-[(2-fluoro-3-methoxyphenyl)methyl]-2-methyl-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)imidazole-4-carboxamide ::US10364238, Example 121::US11001578, Example 121::US11084809, Example 121::US11198691, Example 121 Plasma kallikrein Human 43.9 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408801 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408801&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365087 406799432 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073179 COc1cccc(CNC(=O)c2cn(Cc3ccc(Cn4ccccc4=O)cc3)c(C)n2)c1F InChI=1S/C26H25FN4O3/c1-18-29-22(26(33)28-14-21-6-5-7-23(34-2)25(21)27)17-31(18)16-20-11-9-19(10-12-20)15-30-13-4-3-8-24(30)32/h3-13,17H,14-16H2,1-2H3,(H,28,33) XCBLTBHUJNNESG-UHFFFAOYSA-N 408801 N-[(2-fluoro-3-methoxyphenyl)methyl]-2-methyl-1-({4-[(2-oxopyridin-1- yl)methyl]phenyl}methyl)imidazole-4-carboxamide ::US10364238, Example 121::US11001578, Example 121::US11084809, Example 121::US11198691, Example 121 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408801 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408801&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365087 406799432 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073180 COc1cccc(CNC(=O)c2cn(Cc3ccc(Cn4ccccc4=O)cc3)c(n2)C(F)(F)F)c1F InChI=1S/C26H22F4N4O3/c1-37-21-6-4-5-19(23(21)27)13-31-24(36)20-16-34(25(32-20)26(28,29)30)15-18-10-8-17(9-11-18)14-33-12-3-2-7-22(33)35/h2-12,16H,13-15H2,1H3,(H,31,36) UZZGYTADFHNIGM-UHFFFAOYSA-N 408803 N-[(2-fluoro-3-methoxyphenyl)methyl]-1-({4-[(2-oxopyrldin-1- yl)methyl]phenyl}methyl)-2-(trifluoromethyl)imidazole-4-carboxamide ::US10364238, Example 124::US11001578, Example 124::US11084809, Example 124::US11198691, Example 124 Plasma kallikrein Human 191 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408803 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408803&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365057 406799434 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073181 COc1cccc(CNC(=O)c2cn(Cc3ccc(Cn4ccccc4=O)cc3)c(n2)C(F)(F)F)c1F InChI=1S/C26H22F4N4O3/c1-37-21-6-4-5-19(23(21)27)13-31-24(36)20-16-34(25(32-20)26(28,29)30)15-18-10-8-17(9-11-18)14-33-12-3-2-7-22(33)35/h2-12,16H,13-15H2,1H3,(H,31,36) UZZGYTADFHNIGM-UHFFFAOYSA-N 408803 N-[(2-fluoro-3-methoxyphenyl)methyl]-1-({4-[(2-oxopyrldin-1- yl)methyl]phenyl}methyl)-2-(trifluoromethyl)imidazole-4-carboxamide ::US10364238, Example 124::US11001578, Example 124::US11084809, Example 124::US11198691, Example 124 Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408803 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408803&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365057 406799434 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073182 COc1cccc(CNC(=O)c2cn(Cc3ccc(nc3)N3CCCC3)nc2C(F)(F)F)c1F InChI=1S/C23H23F4N5O2/c1-34-18-6-4-5-16(20(18)24)12-29-22(33)17-14-32(30-21(17)23(25,26)27)13-15-7-8-19(28-11-15)31-9-2-3-10-31/h4-8,11,14H,2-3,9-10,12-13H2,1H3,(H,29,33) CWABZPWKGAMQLS-UHFFFAOYSA-N 408804 N-[(2-fluoro-3-methoxyphenyl)methyl]-1-{[6-(pyrrolidin-1-yl)pyridin-3-yl]methyl}-3- (trifluoromethyl)pyrazole-4-carboxamide::US10364238, Example 126::US11001578, Example 126::US11084809, Example 126::US11180484, Reference Example G Plasma kallikrein Human 742 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408804 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408804&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365050 406799435 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073183 COc1cccc(CNC(=O)c2cn(Cc3ccc(nc3)N3CCCC3)nc2C(F)(F)F)c1F InChI=1S/C23H23F4N5O2/c1-34-18-6-4-5-16(20(18)24)12-29-22(33)17-14-32(30-21(17)23(25,26)27)13-15-7-8-19(28-11-15)31-9-2-3-10-31/h4-8,11,14H,2-3,9-10,12-13H2,1H3,(H,29,33) CWABZPWKGAMQLS-UHFFFAOYSA-N 408804 N-[(2-fluoro-3-methoxyphenyl)methyl]-1-{[6-(pyrrolidin-1-yl)pyridin-3-yl]methyl}-3- (trifluoromethyl)pyrazole-4-carboxamide::US10364238, Example 126::US11001578, Example 126::US11084809, Example 126::US11180484, Reference Example G Kallikrein-1 Human >10000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408804 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408804&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365050 406799435 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073184 CN1CC(CNC(=O)c2cn(Cc3ccc(Cn4ccccc4=O)cc3)nc2N)Oc2cc(Cl)ccc12 InChI=1S/C27H27ClN6O3/c1-32-16-21(37-24-12-20(28)9-10-23(24)32)13-30-27(36)22-17-34(31-26(22)29)15-19-7-5-18(6-8-19)14-33-11-3-2-4-25(33)35/h2-12,17,21H,13-16H2,1H3,(H2,29,31)(H,30,36) BZQHROALKROIIJ-UHFFFAOYSA-N 408805 3-amino-N-[(7-chloro-4-methyl-2,3-dihydro-1,4-benzoxazin-2-yl)methyl]-1-({4-[(2- oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 139::US11001578, Example 139::US11084809, Example 139::US11198691, Example 139 Plasma kallikrein Human 64.7 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408805 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408805&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365007 406799436 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073185 CN1CC(CNC(=O)c2cn(Cc3ccc(Cn4ccccc4=O)cc3)nc2N)Oc2cc(Cl)ccc12 InChI=1S/C27H27ClN6O3/c1-32-16-21(37-24-12-20(28)9-10-23(24)32)13-30-27(36)22-17-34(31-26(22)29)15-19-7-5-18(6-8-19)14-33-11-3-2-4-25(33)35/h2-12,17,21H,13-16H2,1H3,(H2,29,31)(H,30,36) BZQHROALKROIIJ-UHFFFAOYSA-N 408805 3-amino-N-[(7-chloro-4-methyl-2,3-dihydro-1,4-benzoxazin-2-yl)methyl]-1-({4-[(2- oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 139::US11001578, Example 139::US11084809, Example 139::US11198691, Example 139 Kallikrein-1 Human >40000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408805 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408805&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365007 406799436 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1 1073186 Nc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCC1CNc2ccc(Cl)cc2O1 InChI=1S/C26H25ClN6O3/c27-19-8-9-22-23(11-19)36-20(12-29-22)13-30-26(35)21-16-33(31-25(21)28)15-18-6-4-17(5-7-18)14-32-10-2-1-3-24(32)34/h1-11,16,20,29H,12-15H2,(H2,28,31)(H,30,35) PIQXYEUIEZKEKB-UHFFFAOYSA-N 408806 3-amino-N-[(7-chloro-3,4-dihydro-2H-1,4-benzoxazin-2-yl)methyl]-1-({4-[(2- oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 140::US11001578, Example 140::US11084809, Example 140::US11198691, Example 140 Plasma kallikrein Human 10.6 US Patent 10.7270/Q29G5R07 aid1805793 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408806 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=336&target=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408806&enzyme=Plasma+kallikrein&column=ki&startPg=0&Increment=50&submit=Search 121365122 406799437 1 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA 6O1G,6T7P Plasma kallikrein KLKB1_HUMAN P03952 A6NH96 B2R8H9 Q17RE8 Q17RE9 Q4W5C3 1073187 Nc1nn(Cc2ccc(Cn3ccccc3=O)cc2)cc1C(=O)NCC1CNc2ccc(Cl)cc2O1 InChI=1S/C26H25ClN6O3/c27-19-8-9-22-23(11-19)36-20(12-29-22)13-30-26(35)21-16-33(31-25(21)28)15-18-6-4-17(5-7-18)14-32-10-2-1-3-24(32)34/h1-11,16,20,29H,12-15H2,(H2,28,31)(H,30,35) PIQXYEUIEZKEKB-UHFFFAOYSA-N 408806 3-amino-N-[(7-chloro-3,4-dihydro-2H-1,4-benzoxazin-2-yl)methyl]-1-({4-[(2- oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide ::US10364238, Example 140::US11001578, Example 140::US11084809, Example 140::US11198691, Example 140 Kallikrein-1 Human >40000 US Patent 10.7270/Q29G5R07 aid1805794 US11084809 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST 8/10/2021 1/24/2022 KalVista Pharmaceuticals Limited http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=408806 http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=pol&polymerid=8441&target=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search http://www.bindingdb.org/jsp/dbsearch/PrimarySearch_ki.jsp?energyterm=kJ/mole&tag=r21&monomerid=408806&enzyme=Kallikrein-1&column=ki&startPg=0&Increment=50&submit=Search 121365122 406799437 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS 1SPJ Kallikrein-1 KLK1_HUMAN P06870 Q66US9 Q86U61 Q8TCV8 Q9BS53 Q9NQU4 Q9UD19 Q9UMJ1